

CURRICULUM VITAE
University of Florida College of Medicine

BIOGRAPHICAL

Name: Kirk P. Conrad

Home Address: 7802 NW 56th Way
Gainesville, FL 32653

Birth Place: Ann Arbor, MI

Home Phone: 352-375-2281

Citizenship: USA

Business Address: Department of Physiology
and Functional Genomics
University of Florida College of Medicine
1600 SW Archer Road
M552 PO Box 100274
Gainesville, FL 32610-0274

E-Mail Address: kpconrad@ufl.edu **Business Phone:** 352-392-2798 **Business Fax:** 352-846-0270

EDUCATION and TRAINING

UNDERGRADUATE:

1973-1977 Bowdoin College, Brunswick, ME B.A. Biochemistry

GRADUATE:

1977-1980 Dartmouth Medical School, Hanover, NH M.D.

POST-GRADUATE:

1985-1987 Case Western Reserve University Postdoctoral Fellow/Visiting Instructor
Department of Medicine (with Mike J. Dunn, M.D.)
Division of Nephrology
Cleveland, OH

1981-1984 Dartmouth Medical School Postdoctoral Fellow
Department of Physiology (with Heinz Valtin, M.D. & Miklos Gellai, B.S.)
Hanover, NH

1980-1981 University of Colorado Medical Internship
Health Sciences Center (Robert W. Schrier, M.D., Chairman)
Denver, CO

APPOINTMENTS and POSITIONS

ACADEMIC:

1984-1990	Department of Physiology Dartmouth Medical School Hanover, NH	Assistant Professor
1990-1992	Departments of Physiology, and of Obstetrics and Gynecology University of New Mexico School of Medicine Albuquerque, NM	Assistant Professor
1992-1994	Departments of Physiology, and of Obstetrics and Gynecology University of New Mexico School of Medicine Albuquerque, NM	Associate Professor
1994-1998	Magee-Womens Research Institute University of Pittsburgh School of Medicine Pittsburgh, PA	Associate Investigator
1994-1999	Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA	Associate Professor
1996-1999	Department of Cell Biology and Physiology University of Pittsburgh School of Medicine (Secondary Appointment) Pittsburgh, PA	Associate Professor
1996	Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Research Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA	Appointment to Tenure
1998	Magee-Womens Research Institute University of Pittsburgh School of Medicine Pittsburgh, PA	Senior Investigator
2000-2006	Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA	Professor
2000-2006	Department of Cell Biology and Physiology University of Pittsburgh School of Medicine (Secondary Appointment)	Professor

Pittsburgh, PA

2004	Sabbatical Leave to the Department of Zoology University of Melbourne, Parkville, Victoria, Australia with Laura J. Parry, PhD	Honorary Fellow
2006	Department of Physiology and Functional Genomics University of Florida College of Medicine	Professor with Tenure
2007	Department of Ob/Gyn University of Florida College of Medicine (Secondary Appointment)	Professor
2016	J. Robert and Mary Cade Professor of Physiology	

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

American Physiological Society	1985
American Society of Nephrology	1985-2012
Society for Gynecologic Investigation	1989
International Society for the Study of Hypertension in Pregnancy	1990
Perinatal Research Society	1996

HONORS and AWARDS

James Bowdoin Scholar Honor Society	1976
Magna Cum Laude	1977
Alpha Omega Alpha Honor Society	1979
Good Physicians Award (Dartmouth Medical School)	1980
Physician Scientist Award, NIH K11 HD00662	1985-1990
8 th Mallinckrodt Scholar Award	1988-1993
Outstanding Teacher Award in the Basic Sciences	1990
Flinn Newly Independent Investigator Award (AHA)	1991-1994
Basic Medical Sciences Teaching Award presented by the UNM School of Medicine Graduates	1993
Research Career Development Award, NIH K04 HD01098	1995-1999
Ernest H. Starling Distinguished Lectureship of the American Physiological Society Water & Electrolyte Homeostasis Section	2010
Liley Lecturer Perinatal Research Society	2010
Senior Faculty Research Award University of Florida Chapter Sigma Xi	2010
Dutch Heart Foundation Lecturer	2012
University of Florida College of Medicine Exemplary Teacher Award	2013, 2014, 2016
J. Robert and Mary Cade Professor of Physiology	2016
University of Florida Term Professorship	2018-2021

PUBLICATIONS

Peer-Reviewed:

1. **Conrad K.P.**, Brinck-Johnsen T., Gellai M. and Valtin H. Renal autoregulation in chronically catheterized, conscious rats. **Am. J. Physiol.** 247 (**Renal Fluid Electrolyte Physiol** 16): F229-F233, 1984.
2. **Conrad K.P.** Renal hemodynamics during pregnancy in chronically catheterized, conscious rats. **Kidney Int.** 26:24-29,1984.
3. Robinson D.H., **Conrad K.P.** and Edwards B.R. Comparison of body fluid compartment sizes in Brattleboro homozygous and Long-Evans rats. **Am J. Physiol.** 247 (**Renal Fluid Electrolyte Physiol.** 16): F234-F239, 1984.
4. **Conrad K.P.** and Colpoys M.C. Evidence against the hypothesis that prostaglandins are the vasodepressor agents of pregnancy. Serial studies in chronically instrumented, conscious rats. **J. Clin. Invest.** 77: 236-245, 1986.
5. **Conrad K.P.**, Gellai M., North W.G. and Valtin H. Influence of oxytocin on renal hemodynamics and electrolyte and water excretion. **Am. J. Physiol.** 251 (**Renal Fluid Electrolyte Physiol.** 20): F290-F296, 1986.
6. **Conrad K.P.** Possible mechanisms for changes in renal hemodynamics during pregnancy: studies from animal models. **Am. J. Kidney Diseases** 9:253-259, 1987 (*Invited Review*).
7. **Conrad K.P.** and Dunn M.J. Renal synthesis and urinary excretion of eicosanoids during pregnancy in rats. **Am. J. Physiol.** 253 (**Renal Fluid Electrolyte Physiol.** 22): F1197-F1205, 1987.
8. Decker M., **Conrad K.P.** and Strohl K.P. Noninvasive oximetry in the rat. **Biomed. Instrumentation Technol.** 23:222-228,1989.
9. **Conrad K.P.**, Morganelli P.M., Brinck-Johnsen T. and Colpoys M.C. The renin-angiotensin system during pregnancy in chronically instrumented, conscious rats. **Am. J. Obstet. Gynecol.** 161:1065-1072, 1989.
10. **Conrad K.P.** and Vernier K.A. Plasma level, urinary excretion and metabolic production of cGMP during gestation in rats. **Am. J. Physiol.** 257 (**Regulatory Integrative Comp. Physiol.** 26): R847-R853, 1989.
11. **Conrad K.P.** Animal models of preeclampsia: do they exist? **Fetal Med. Rev.** 2:67-89, 1990 (*Invited Review*).
12. Brandt M.A. and **Conrad K.P.** In vivo and in vitro studies of a putative inhibitor of cyclic guanosine 3', 5'-monophosphate production. **Proc. Soc. Exp. Biol. Med.** 196:30-35,1991.
13. **Conrad K.P.**, Barrera S.A., Friedman P.A. and Schmidt V.M. Evidence for attenuation of myo-inositol uptake, phosphoinositide turnover and inositol phosphate production in aortic vasculature of rats during pregnancy. **J. Clin. Invest.** 87:1700-1709,1991.
14. **Conrad K.P.** and Russ R.D. Augmentation of baroreflex-mediated bradycardia in conscious pregnant rats. **Am. J. Physiol.** 262 (**Regulatory Integrative Comp. Physiol.** 31): R472-R477, 1992.
15. **Conrad K.P.** and Whittemore S.L. N^G-monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. **Am. J. Physiol.** 262 (**Regulatory Integrative Comp. Physiol.** 31): R1137-R1144, 1992.
16. Gilson G.J., Mosher M.D. and **Conrad K.P.** Systemic hemodynamics and oxygen transport during pregnancy in chronically instrumented, conscious rats. **Am. J. Physiol.** 263 (**Heart Circ. Physiol.** 32): H1911-H1918, 1992.
17. **Conrad K.P.** Renal changes in pregnancy. **Urol. Ann.** 6:313-340, 1992 (*Invited Review*).
18. **Conrad K.P.**, Joffe G.M., Kruszyna H., Kruszyna R., Rochelle L.G., Smith R.P., Chavez J.E. and Mosher M.D. Identification of increased nitric oxide biosynthesis during pregnancy in rats. **FASEB J.** 7:566-571,1993.
19. Del Valle G.O., Mosher M.D. and **Conrad K.P.** Serum immunoreactive erythropoietin and red cell mass during pregnancy in conscious rats. **Am. J. Physiol.** 265 (**Regulatory Integrative Comp. Physiol.** 34): R399-R403, 1993.
20. Griggs K.C., **Conrad K.P.**, Mackey K. and McLaughlin M.K. Endothelial modulation of renal interlobar arteries from pregnant rats. **Am. J. Physiol.** 265 (**Renal Fluid Electrolyte Physiol.** 34): F309-F315, 1993.

21. **Conrad K.P.**, Vill M., McGuire P.G., Dail W.G. and Davis A.K. Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi. **FASEB J.** 7:1269-1276,1993.
22. **Conrad K.P.**, Mosher M.D., Brinck-Johnson T. and Colpoys M.C. Effects of 17 β -estradiol and progesterone on pressor responses in conscious ovariectomized rats. **Am. J. Physiol.** 266 (**Regulatory Integrative Comp. Physiol.** 35): R1267-R1272, 1994.
23. Whittemore S.L., McLaughlin M.K., Davidge S.T. and **Conrad K.P.** Effect of pregnancy on vascular cGMP production and vasorelaxation in the rat. **Hypertension in Pregnancy** 13:227-244,1994.
24. Gough S.R., Mosher M.D. and **Conrad K.P.** Metabolism of erythropoietin in conscious pregnant rats. **Am. J. Physiol.** 268 (**Regulatory Integrative Comp. Physiol.** 37): R1117-R1120, 1995.
25. **Conrad K.P.** and Davis A.K. Nitric oxide synthase activity in placentas from women with preeclampsia. **Placenta** 16:691-699,1995.
26. McLaughlin M.K. and **Conrad K.P.** Nitric oxide biosynthesis during pregnancy: implications for circulatory changes. **Clin. Exper. Pharmacol. Physiol.** 22:164-171, 1995 (*Invited Review*).
27. *Danielson L.A. and **Conrad K.P.** Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. **J. Clin. Invest.** 96:482-490,1995.
28. Baylis C., Suto T. and **Conrad K.P.** Importance of nitric oxide in control of systemic and renal hemodynamics during pregnancy; studies in the rat and implications for preeclampsia. **Hypertension in Pregnancy** 15:147-169, 1996 (*Invited Review*).
29. **Conrad K.P.**, Benyo D.F., Westerhausen-Larson A. and Miles T.M. Expression of erythropoietin by the human placenta. **FASEB J.** 10:760-768,1996.
30. Danielson L.A. and **Conrad K.P.** Prostaglandins maintain renal vasodilation and hyperfiltration during chronic nitric oxide synthase blockade in conscious pregnant rats. **Circ. Res.** 79:1161-1166,1996.
31. Benyo D.F., Miles T.M. and **Conrad K.P.** Hypoxia stimulates cytokine production by villous explants from the human placenta. **J. Clin. Endocrinol. Metab.** 82:1582-1588,1997.
32. **Conrad K.P.** and Benyo D.F. Placental cytokines and the pathogenesis of preeclampsia. **Am. J. Reprod. Immunol.** 37:240-249, 1997 (*Invited Review*).
33. Sladek S.M., Magness R.R. and **Conrad K.P.** Nitric oxide and pregnancy. **Am. J. Physiol.** 272 (**Regulatory Integrative Comp. Physiol.** 41): R441-R463, 1997 (*Invited Review*).
34. Gandley R.E., Griggs K.C., **Conrad K.P.** and McLaughlin M.K. Intrinsic tone and passive mechanics of isolated renal arteries from virgin and late-pregnant rats. **Am. J. Physiol.** 273 (**Regulatory Integrative Comp. Physiol.** 42): R22-R27, 1997.
35. **Conrad K.P.**, Miles T.M. and Benyo D.F. Circulating levels of cytokines in women with preeclampsia. **Am. J. Reprod. Immunol.** 40:102-111,1998.
36. Benyo D.F., and **Conrad K.P.** Expression of the erythropoietin receptor by trophoblast cells in the human placenta. **Biol. Reprod.** 60:861-870,1999.
37. *Danielson L.A. Sherwood O.D. and **Conrad K.P.** Relaxin is a potent renal vasodilator in conscious rats. **J. Clin. Invest.** 103:525-533,1999.
38. **Conrad K.P.**, Gandley R.E., Ogawa T., Nakanishi S. and Danielson L.A. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. **Am. J. Physiol.** 276 (**Renal Physiol.** 45): F767-F776, 1999.
39. **Conrad K.P.**, Kerchner L.J. and Mosher M.D. Plasma and 24-hour urinary NO_x and cGMP in normal pregnancy and preeclampsia in women on a reduced-NO_x diet. **Am. J. Physiol.** 277 (**Renal Physiol.** 46): F48-F57, 1999.
40. Martin D. and **Conrad K.P.** Expression of endothelial nitric oxide synthase by extravillous trophoblast cells in the human placenta. **Placenta** 21:23-31,2000.
41. Rajakumar A.R. and **Conrad K.P.** Expression, ontogeny and regulation of hypoxia inducible transcription factors in the human placenta. **Biol. Reprod.** 63:559-569, 2000.
42. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats. **Am. J. Physiol.** 279 (**Regulatory Integrative Comp. Physiol.**): R1298-R1304, 2000.

43. Rajakumar, R.A., Whitelock, K.A., Daftary, A.R., Markovic, N. and **Conrad K.P.** Overexpression of the hypoxia-inducible transcription factors HIF-1 α and HIF-2 α , in placentas from women with preeclampsia. **Biol. Reprod.** 64:499-506, 2001, and Erratum **Biol. Reprod.** 64: 1019-1020, 2001.
44. Gandley R.E., **Conrad K.P.** and McLaughlin M.K. Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. **Am J Physiol Regulatory Integrative Comp Physiol** 280:R1-R7, 2001.
45. Benyo D.F., Smarason A., Redman C.W.G., Sims C. and **Conrad K.P.** Expression of inflammatory cytokines in placentas from women with preeclampsia. **J. Clin. Endocrinol. Metab.** 86:2505-2512, 2001.
46. Novak J., Danielson L.A., Kerchner L.A., Sherwood O.D., Ramirez R.J., Moalli P.A. and **Conrad K.P.** Relaxin is essential for renal vasodilation during pregnancy in conscious rats. **J. Clin. Invest.** 107:1469-1475, 2001.
47. **Conrad K.P.**, Davis A.K., Powers R.W. and Novak J.N. Citrulline is not the major product using the standard "nitric oxide synthase activity" assay on renal cortical homogenates. **Am. J. Physiol. Regulatory Integrative Comp. Physiol.** 282:R330-R310, 2002.
48. *Novak J., Ramirez R.J.J., Gandley R.E., Sherwood O.D. and **Conrad K.P.** Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. **Am. J. Physiol. Regulatory Integrative Comp. Physiol.** 283:R349-R355, 2002.
49. Rajakumar A., Doty K., Daftary A., Harger G. and **Conrad K.P.** Impaired oxygen-dependent reduction of HIF-1 α and -2 α proteins in preeclamptic placentae. **Placenta** 24:199-208, 2003.
50. Danielson L.A. and **Conrad K.P.** Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. **J. Appl. Physiol.** 95:1509-1514, 2003.
51. Jeyabalan A., Novak J., Danielson L.A., Kerchner L.J., Opett S.L. and **Conrad K.P.** Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. **Circ. Res.** 93:1249-1257, 2003.
52. Powers R.W., Majors A.K., Kerchner L.J. and **Conrad K.P.** Renal handling of homocysteine during normal pregnancy and preeclampsia. **J. Soc. Gynecol. Invest.** 11:45-50, 2004.
53. **Conrad K.P.** Mechanisms of renal vasodilation and hyperfiltration during pregnancy. **J. Soc. Gynecol. Invest.**, 11:438-48, 2004 (*Invited Review*).
54. **Conrad K.P.** and Novak J. The emerging role of relaxin in renal and cardiovascular function. **Am. J. Physiol.** 287:R250-R261, 2004 (*Invited Review*).
55. Novak J., Rajakumar A., Miles T.M. and **Conrad K.P.** Nitric oxide synthase isoforms in the rat kidney during pregnancy. **J. Soc. Gynecol. Invest.** 11:280-288, 2004.
56. **Conrad K.P.**, Debrah D.O., Novak J., Danielson L.A. and Shroff S.G. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. **Endocrinol.** 145:3289-3296, 2004.
57. Rajakumar A., Brandon H.M., Daftary A., Ness R. and **Conrad K.P.** Evidence for the functional activity of hypoxia inducible transcription factors overexpressed in preeclamptic placentae. **Placenta** 25:763-9, 2004.
58. Davison J.M., Volker H., Jeyabalan A., **Conrad K.P.**, Karumanchi S.A., Quaggin S., Dechend R. and Luft F.C. Current ideas on preeclampsia. **J. Am. Soc. Nephrol.** 15:2440-8, 2004 (*Invited Review*).
59. Debrah D.O., **Conrad K.P.**, Danielson, L.A. and Shroff S.G. Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. **J. Appl. Physiol.** 98:1013-1020, 2005.
60. Kerchner L.J., Novak J., Hanley-Yanez, K., Doty K.D. and **Conrad K.P.** Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. **Endocrinol.** 146:2791-7, 2005.
61. Debrah D.O., **Conrad K.P.**, Jeyabalan A., Danielson L.A. and Shroff S.G. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. **Hypertension** 46:745-750, 2005.
62. **Conrad K.P.**, Novak J., Danielson L.A., Kerchner L.J., and Jeyabalan A. Mechanisms of renal vasodilation and hyperfiltration during pregnancy: current perspectives and potential implications for preeclampsia. **Endothelium** 12:57-62, 2005 (*Invited Review*).
63. Rajakumar A., Doty K.D., Daftary A., Markovic N. and **Conrad K.P.** Expression of von Hippel Lindau protein in placentae from women with normal pregnancy and preeclampsia. **Placenta** 27:411-421. 2006.

64. Smith M.C., Murdoch A.P., Danielson L.A., **Conrad K.P.** and Davison J.M. Relaxin has a role in establishing a renal response in pregnancy. **Fertility and Sterility** 86:253-255, 2006.
65. Jeyabalan A., Kerchner L.J., Fisher M.C., McGuane J.T., Doty K.D. and **Conrad K.P.** Matrix metalloproteinase-2 activity, protein, mRNA and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. **J. Appl. Physiol.** 100:1955-1963, 2006.
66. * Smith M.C., Danielson L.A., **Conrad K.P.** and Davison J.M. Influence of recombinant human relaxin on renal haemodynamics in humans. **J. Am. Soc. Nephrol.** 17: 3192-7, 2006.
67. Novak J., Parry L.J., Matthews J., Kerchner L.J., Indovina K., Hanley-Yanez K., Doty K.D., Debrah D.O., Shroff S.G. and **Conrad K.P.** Evidence for local relaxin ligand-receptor expression and function in arteries. **FASEB J.** 20: 2352-62, 2006.
68. Debrah D.O., Novak J., Matthews J.E., Ramirez R.J., Shroff S.G. and **Conrad K.P.** Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. **Endocrinol.** 147: 5126-31, 2006.
69. Jeyabalan A., Novak J., Doty K.D., Matthews J., Fisher M.C., Kerchner L.J. and **Conrad K.P.** Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short term administration of relaxin. **Endocrinol.** 148: 189-97, 2007.
70. Rajakumar A., Jeyabalan A., Markovic N., Ness R., Gilmore C. and **Conrad K.P.** Placental HIF-1 α , HIF-2 α , membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late onset intrauterine growth restriction. **Am. J. Physiol. Regulatory Integrative Comp. Physiol.** 293: R766-74, 2007.
71. Rajakumar A., Michael M.M., Daftary A., Jeyabalan A., Gilmour A. and **Conrad K.P.** Proteasomal Activity in Placentas from Women with Preeclampsia and Intrauterine Growth Restriction: Implications for Expression of HIF-alpha Proteins. **Placenta** 29: 290-9, 2008.
72. Teichman S.L., Unemori E., Dschietzig T., **Conrad, K.**, Voors A.A., Teerlink J.R., Felker M.G., Metra M., and Cotter G. Relaxin, a pleiotrophic vasodilator for the treatment of heart failure. **Heart Failure Rev.** DOI 10.1007/s10741-008-9129-3. 20 December 2008.
73. Founds S.A., Conley Y.P., Lyons-Weiler J.F., Jeyabalan A., Hogge W.A. and **Conrad K.P.** Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. **Placenta** 30: 15-24, 2009.
74. **Conrad K.P.** Unveiling the vasodilatory actions and mechanisms of relaxin. **Hypertension** 56:2-9, 2010 (*Invited Review*).
75. Founds S. A., Terhorst L. A., **Conrad K.P.**, Hogge W. A., Jeyabalan A. and Conley Y. P. Gene expression of eight candidates in first trimester preeclampsia placenta. **Biological Research for Nursing** 13:134-139, 2011.
76. McGuane J.T., Debrah J.E., Sautina L., Rubin J.P., Novak J., Segal M.S. and **Conrad K.P.** Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. **Endocrinol.** 152:2786-96, 2011.
77. McGuane J.T., Danielson L.A., Debrah J.E., Rubin J.P., Novak J. and **Conrad K.P.** Angiogenic growth factors are new players in the sustained relaxin vasodilatory pathway in rodents and humans. **Hypertension** 57:1151-60, 2011.
78. **Conrad K.P.** Emerging role of relaxin in the maternal adaptations to normal pregnancy: Implications for preeclampsia. **Seminars Nephrol.** 31: 15-32, 2011 (*Invited Review*).
79. **Conrad K.P.** 2010 Ernest H. Starling Lectureship. Maternal vasodilation in pregnancy: the emerging role of relaxin. **Am J Physiol. Regulatory Integrative Comp. Physiol.** 301:R267-275, 2011 (*Invited Review*).
80. Debrah D.O., Debrah J.E., Haney J.L., McGuane J.T., Sacks M.S., **Conrad K.P.** and Shroff S.G. Relaxin regulates vascular wall mechanical properties and remodeling in mice. **J Appl Physiol.** 111:260-71, 2011.
81. **Conrad K.P.** and Shroff S.G. Effects of relaxin on arterial tone and remodeling. **Mediators Mechanisms, and Pathways in Tissue Injury** section of *Current Hypertension Reports* (Volume 13, Issue 6). Taegtmeyer and Atlas, eds., 2011 (*Invited Review*).

82. * Segal M.S., Sautina L., Li S., Diao Y., Agoulnik A.I., Kielczewski J, McGuane J.T., Grant M.B., and **Conrad K.P.** Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. **Blood** 119:629-36, 2012.
83. McGuane J.T. and **Conrad K.P.** GPCRs as potential therapeutic targets in preeclampsia. **Drug Discover Today: Disease Models**. 9(3):e119-e127, 2012 (*Invited Review*).
84. Vodstrcil L.A., Tare M., Novak J., Dragomir N., Ramirez R.J., Wlodek M.E., **Conrad K.P.**, and Parry L.J. Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow. **FASEB J**. 26:4035-44, 2012.
85. Soh Y.M., Tiwari A., Mahendroo M., **Conrad K.P.**, and Parry L.J. Relaxin regulates hyaluronan synthesis and aquaporins in the cervix of late pregnant mice. **Endocrinol**. 153:6054-64, 2012.
86. **Conrad K.P.** and Baker V.L. Corpus luteal contribution to maternal pregnancy physiology and outcomes in assisted reproductive technologies. **Am. J. Physiol. Regulatory Integrative Comp. Physiol**. 304:R69-72, 2013 (*Perspectives*).
87. Jelinic M., Leo C.H., Post Uiterweer E.D., Sandow S.L., Gooi J.H., Wlodek M.E., **Conrad K.P.**, Parkington H., Tare M., and Parry L.J. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after *in vivo* relaxin treatment. **FASEB J**. 28:275-87, 2014.
88. **Conrad KP** and Davison JM. The renal circulation in normal pregnancy and preeclampsia. **Am J Physiol. Renal Fluid and Electrolyte Physiol**. 306:F1121-35, 2014 (*Invited Review*).
89. Rabaglino MB, Post Uiterweer ED, Jeyabalan A, Hogge WA, and **Conrad KP**. A bioinformatics approach reveals evidence for impaired endometrial maturation before and during early pregnancy in women who developed preeclampsia. **Hypertension** 65:421-429, 2015.
90. Jelinic M, Tare M, **Conrad KP**, and Parry LJ. Differential effects of relaxin deficiency on vascular aging in arteries of male mice. **Age** 37(4):66,1-12.doi: 10.1007/s11357-015-9803-z, 2015.
91. Kaftanovskaya EM, Huang Z, Lopez C, **Conrad K**, Agoulnik AI. Conditional deletion of the relaxin receptor gene in cells of smooth muscle cell lineage affects lower reproductive tract in pregnant mice. **Biol. Reprod**. 92(4):91,1-9, 2015
92. Baker VL, Brown MB, Luke B, and **Conrad KP**. Association of number of retrieved oocytes with live birth rate and birth weight: an analysis of 231,815 cycles of in vitro fertilization. **Fertil Steril**. 103: 931-938, 2015.
93. **Conrad KP**. G-protein coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin-insulin-like family peptide receptor 1 for treatment and prevention. **Human Reproduction Update** 22:647-664, 2016 (*Invited review*).
94. Leo CH, Jelinic M, Ng HH, Marshall SA, Novak J, Tare M, **Conrad KP**, Parry LJ. Vascular actions of relaxin: nitric oxide and beyond. **Br. J Pharmacol**. 174:1002-1014, 2017
95. Oluseyi Ogunleye O, Campo B, Herrera D, Post Uiterweer ED, and **Conrad KP**. Relaxin confers cytotrophoblast protection from hypoxia-reoxygenation injury through the Phosphatidylinositol 3-kinase/Akt-Protein Kinase B cell survival pathway. **Am J Physiol**. 312:R559-R568, 2017.
96. Petersen JW, Liu J, Chi Y-Y, Lingis MD, Williams RS, Rhoton-Vlasak A, Hamilton KA, Segal MS, **Conrad KP**. Comparison of multiple non-invasive methods of measuring cardiac output during pregnancy reveals marked heterogeneity in the magnitude of cardiac output change between women. **Physiol. Reports** Apr;5(8). pii: e13223. doi: 10.14814/phy2.13223, 2017.
97. **Conrad KP**, Rabaglino MR, Post Uiterweer ED. Emerging role for dysregulated decidualization in the genesis of preeclampsia. **Placenta** 60:119-129, 2017 (*Invited Review*).
98. Deng A, **Conrad K** and Baylis C. Relaxin mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure. **Am J Physiol**. 314:R147-R152, 2017.
99. Kilar CR, Diao Y, Sautina L, Sekharan S, Keinan S, **Conrad KP**, Mohandas R. Segal MS. Activation of the β -common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles. **Physiol. Reports** Jun;6(12):e13751. doi: 10.14814/phy2.13751, 2018.
100. von Versen-Höynck F, Strauch NK, Fleischmann R, Liu J, **Conrad KP**, and Baker VL. Effect of corpora lutea number on renal electrolyte levels in early pregnancy. **Reproductive Sci.**, in press

101. von Versen-Höynck F, Narasimhan P, Elif Seda Selamat Tierney ESS, Martinez N, **Conrad KP**, Baker VL, Winn VD. Absent or excessive corpus luteum number is associated with altered maternal vascular health in early pregnancy. **Hypertension**, in press.
102. von Versen-Höynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, **Conrad KP**, Baker VL. Increased preeclampsia risk and reduced aortic compliance with in vitro fertilization cycles in the absence of a corpus luteum. **Hypertension**, in press.
103. Rodriguez CR, Chi YY, Chiu KH, Zhai X, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols WW, Petersen JW, Segal MS, **Conrad KP**, Mohandas R. Wave reflections and global arterial compliance during normal human pregnancy. **Physiol. Reports**, in press.
104. **Conrad KP**, Taher S, Borja Y, Cabanela L, Costers VJ, Carson MW, Bailes JC, Dhar, B, Beckworth MT, Rabaglino MB, Post Uiterweer ED. CCK, Gastrin, CCKAR/BR and Bitter Taste Receptor, TAS2R14: Trophoblast expression and signaling. **Am J Physiol**, in revision.
105. Rabaglino MB, **Conrad KP**. Evidence for common molecular pathways of dysregulated decidualization in preeclampsia and endometrial disorders. **Hypertension**, submitted.

*These works received an Editorial or Commentary

Proceedings of Conferences and Symposia and Book Chapters:

1. **Conrad K.P.** and Dunn M.J. Renal prostaglandins and other eicosanoids. In: E.E. Windhager ed. **Handbook of Physiology**: Section 8: Renal Physiology, Vol. II., New York; Oxford University Press, pp. 1707-1757, 1991.
2. **Conrad K.P.**, Gellai M., North W.G. and Valtin H. Influence of oxytocin on renal hemodynamics and sodium excretion. **Ann. N.Y. Acad. Sci.** 689:346-362, 1993.
3. **Conrad K.P.** and Lindheimer M.D. Renal and cardiovascular changes in normal pregnancy and preeclampsia. In: **Chesley's Hypertensive Disorders in Pregnancy: Second Edition**. Chapter 8. Lindheimer, M.D., Cunningham, F.G. and Roberts, J.M. (eds.). Appleton & Lange; Stamford, CT, pp. 263-326, 1999.
4. **Conrad K.P.**, Danielson L.A., Novak J.N., Kerchner L.J., Gandley R.E., Sherwood O.D., Ramirez R.J and Moalli P.A. Is relaxin the "elusive" renal vasodilator of pregnancy? In: **Relaxin 2000 - 3rd International Conference on Relaxin & Related Peptides** Tregear, G.W., Ivell, R., Bathgate, R.A., and Wade, J.D., editors. Kluwer Academic Publishers, Netherlands, p. 169-176, 2001.
5. Debrah D.O., **Conrad K.P.**, Novak J., Danielson L.A., and Shroff S.G. Recombinant human relaxin modifies systemic arterial properties in conscious rats irrespective of gender, but in a biphasic fashion. **Ann. N. Y. Acad. Sci.** 1041: 155-162, 2005.
6. Smith M.C., **Conrad K.P.**, Danielson L.A. and Davison J.M. Renal hemodynamic effects of relaxin in humans. **Ann. N. Y. Acad. Sci.** 1041:163-172, 2005.
7. **Conrad K.P.**, Jeyabalan A., Danielson L.A., Kerchner L.J., and Novak J. Role of relaxin in maternal renal vasodilation of pregnancy. **Ann. N.Y. Acad. Sci.** 1041: 147-154, 2005.
8. Lindheimer M.D., **Conrad K.P.**, and Umans J.J. The Normal and Diseased Kidney in Pregnancy. In: **Diseases of the Kidney and Urinary Tract: Eighth Edition**. Volume 3, Chapter 74. Schrier R.W., editor. Lippincott Williams & Wilkens, U.S.A., 2007.
9. Lindheimer M.D., **Conrad K.P.**, and Karumanchi S.A. Renal Physiology and Disease in Pregnancy. In: **Seldin and Giebisch's The Kidney. Physiology and Pathophysiology: Fourth Edition**. Volume 2, Chapter 83. Robert J. Alpern and Steven C. Hebert, editors. Elsevier, U.S.A., 2007.
10. **Conrad K.P.** Renal Function and Volume Homeostasis. In: **Principles and Practice of Medical Therapy in Pregnancy**, 4th edition. 2007. Gleicher N., ed. www.medicaltherapyinpregnancy.com.
11. Jeyabalan A. and **Conrad K.P.** Renal Function during Normal Pregnancy and Preeclampsia. In: **Frontiers in Bioscience**. Yang, Y. (editor). 12:2425-37, 2007.

12. Jeyabalan A., Novak J., Shroff SG, and **Conrad K.P.** The vascular actions of relaxin. **Adv Exp Med Biol.** 612:65-87, 2007. (Or In: Agoulnik A.I. (editor). **Relaxin and Related Peptides.** Volume 612. Austin/New York: Landes Bioscience/Springer, 2007:65-87).
13. **Conrad K.P.**, Gaber L.W., and Lindheimer M.D. The Kidney in Normal Pregnancy and Preeclampsia. In: **Chesley's Hypertensive Disorders in Pregnancy: Third Edition.** Lindheimer, M.D., Cunningham, F.G. and Roberts, J.M. (eds.). Elsevier. 2009.
14. McGuane J.T., Debrah J.E., Debrah D.O., Rubin J.P., Segal M.S., Shroff S.G., and **Conrad K.P.** The role of relaxin in maternal systemic and renal vascular adaptations during gestation. **Ann. N. Y. Acad. Sci.** 1160:304-12, 2009.
15. Jeyabalan A., and **Conrad K.P.** Renal Physiology and Pathophysiology in Pregnancy. In: **Renal and Electrolyte Disorders.** 7th edition. RW Schrier, ed. Lippincott Williams & Wilkins, Chapter 13, p. 462-518, 2010.
16. **Conrad K.P.** and Karumanchi S.A. Renal Physiology and Disease in Pregnancy. In: **Seldin and Giebisch's The Kidney. Physiology and Pathophysiology: Fifth Edition.** R.J. Alpern, M.J. Caplan, O.W. Moe eds. Academic Press, San Diego. 2689-2761, 2013.
17. **Conrad KP**, Stillman IE., and Lindheimer MD The Kidney in Normal Pregnancy and Preeclampsia. In: **Chesley's Hypertensive Disorders in Pregnancy: Fourth Edition.** Robert N. Taylor, James M. Roberts, F. Gary Cunningham, and Marshall D. Lindheimer (eds.). 4th Edition; Elsevier Academic Press; Chapter 16 pps. 335-377; 2015.

Other Publications:

1. **Conrad K.P.** and Whittemore S.L. Effect of arginine analogues on hemodynamic responses in rats (reply to a letter to the editor). **Am. J. Physiol.** 264 (**Regulatory Integrative Comp. Physiol.** 33): R466-R467, 1993.
2. **Conrad K.P.** The gravid kidney: clues to preeclampsia? **News in Physiological Sciences** 11:192-193, 1996.
3. **Conrad K.P.** Relaxin may be the "elusive" renal vasodilatory agent of normal pregnancy. (Journal Club-Author's reply). **Am. J. Kidney Diseases** 34:1142-1145, 1999.
4. Rajakumar, R.A., Whitelock, K.A., Daftary, A.R., Markovic, N. and **Conrad K.P.** Overexpression of the hypoxia-inducible transcription factors HIF-1 α and HIF-2 α , in placentas from women with preeclampsia. (Erratum.) **Biol. Reprod.** 64: 1019-1020, 2001.
5. **Conrad K.P.** More on the action of relaxin in the renal circulation. **The Relaxin Newsletter** 4:4, 2004.
6. Ilekis JV, Reddy UM, and Roberts JM. Preeclampsia-a pressing problem: An executive summary of a National Institute of Child Health and Human Development Workshop. **Reproductive Sci.** 14:508-523, 2007 (**acknowledged contributor**).
7. Roberts JM, Redman CWG, for the Global Pregnancy Collaboration. Global Pregnancy Collaboration symposium: Prepregnancy and very early pregnancy antecedents of adverse pregnancy outcomes: Overview and recommendations. **Placenta** 60:103-9, 2017 (**acknowledged contributor**).

Abstracts:

1. Edwards B.R., **Conrad K.P.** and Gellai M. Degree of hypertension depends on the method of measurement: serial measurements in trained, chronically-catheterized, conscious SHR rats. **Clin. Res.** 30:510A, 1982.
2. **Conrad K.P.**, Brinck-Johnsen T., Gellai M. and Valtin H. Systemic plasma renin activity (PRA) does not change significantly during renal autoregulation in trained, chronically catheterized, conscious rats. **Kidney Int.** 23:242, 1983.
3. **Conrad K.P.** Renal hemodynamics increase significantly during pregnancy in trained, chronically catheterized conscious rats. **Clin. Res.** 31:514A, 1983.
4. **Conrad K.P.** Renal hemodynamics during late pregnancy in trained, chronically catheterized, conscious rats. **Clin. Res** 31:699A, 1983.

5. **Conrad K.P.** Longitudinal studies of renal hemodynamics during pregnancy in chronically catheterized, conscious rats. *Kidney Int.* 25:287, 1984.
6. **Conrad K.P.** Renal vascular resistance and systemic blood pressure during pregnancy: Serial studies in chronically instrumented, conscious rats. *Clin. Exp. Hypertension B3*:439, 1984.
7. **Conrad K.P.** Alterations in renal vascular resistance and systemic pressure during pregnancy: serial studies in conscious rats. *Clin. Res.* 32:444A, 1984.
8. **Conrad K.P.**, Colpoys M.C. and Veale M. Pressor response during pregnancy: serial studies in chronically instrumented, conscious rats. *Clin. Res.* 32:770A, 1984.
9. **Conrad K.P.** and Colpoys M.C. Systemic and renal vascular response to vasoconstrictors during pregnancy: serial studies in conscious rats. *Kidney Int.* 27:294, 1985.
10. **Conrad K.P.** Effects of indomethacin on renal hemodynamics during pregnancy: serial studies in chronically instrumented, conscious rats. *Clin. Res.* 33:480A, 1985.
11. **Conrad K.P.**, Brinck-Johnsen T. and Adler R.A. Can chronic hyperprolactinemia increase renal hemodynamics? *Clin. Exp. Hypertension B6*: 226, 1987.
12. **Conrad K.P.** and Dunn M.J. Influence of gestation on glomerular prostaglandin synthesis. *Clin. Exp. Hypertension B6*: 75, 1987.
13. **Conrad K.P.** and Brinck-Johnsen T. Influence of captopril on renal hemodynamics and blood pressure during pregnancy in conscious rats. *Kidney Int.* 29:382A, 1986.
14. **Conrad K.P.**, Brinck-Johnsen T. and Adler R.A. Evidence that chronic hyperprolactinemia increases renal hemodynamics. *Clin. Res.* 34:592A, 1986.
15. Morganelli P.M. and **Conrad K.P.** Pressor responsiveness after converting enzyme inhibition during pregnancy. *Clin. Res.* 34:483A, 1986.
16. **Conrad K.P.** and Dunn M.J. Glomerular synthesis of prostaglandins during pregnancy. *Clin. Res.* 34:695A, 1986.
17. **Conrad K.P.** Cyclic nucleotides in pregnancy. *Kidney Int.* 31:421A, 1987.
18. **Conrad K.P.** and Dunn M.J. Urinary excretion and renal synthesis of eicosanoids during pregnancy. *Clin. Res.* 35:544A, 1987.
19. Decker M.J., **Conrad K.P.** and Strohl K.P. Non-invasive oximetry in the rat. *Physiologist* 30:232, 1987.
20. Vernier K.A., Bautista M., Brandt M.A. and **Conrad K.P.** Urinary excretion of cyclic guanosine-3',5'-monophosphate increased during pseudopregnancy in the rat. *Clin. Res* 36:391A, 1988.
21. **Conrad K.P.** Reduced inositol metabolism in gravid rats: possible mechanism for hemodynamic changes during pregnancy. *Soc. Gynecol. Invest.* p. 216, 1988.
22. Brandt M.A. and **Conrad K.P.** 6-anilino-5, 8-quinolinedione (LY83583) decreases plasma levels of cyclic guanosine-3', 5'-monophosphate (cGMP) in conscious rats. *FASEB J* 2:A1066, 1988.
23. **Conrad K.P.** and Vernier K.A. Evidence for reduced inositol metabolism in gravid rats: possible mechanism for hemodynamic changes during pregnancy. *Clin. Res.* 36:480A, 1988.
24. **Conrad K.P.** and Vernier K.A. Evidence for reduced phosphatidylinositol metabolism in gravid rats: possible mechanism for hemodynamic changes during pregnancy. *Clin. Exp. Hypertension B8*: 213, 1989.
25. **Conrad K.P.**, Vernier K.A., Bautista M. and Brandt M.A. Renal excretion of cyclic guanosine-3', 5'-monophosphate increases during pseudopregnancy in the rat. *Clin. Exp. Hypertension B8*: 205, 1989.
26. **Conrad K.P.** and Vernier K.A. Serial study of metabolic clearance rate of cyclic guanosine 3', 5'-monophosphate before, during and after pregnancy in rats. *Clin. Res.* 37:393A, 1989.
27. Whittemore S.L. and **Conrad K.P.** Stimulation of cyclic guanosine-3', 5'-monophosphate (cGMP) production by methacholine differs in aortae from pregnant and virgin rats. *Physiologist* 32:186, 1989.
28. **Conrad K.P.** and Whittemore S.L. N^G-monomethyl-L-arginine (NMA): in vivo and in vitro characterization. *FASEB J* 4:A308, 1990.
29. **Conrad K.P.**, Barrera S.A., Friedman P.A. and Schmidt V.A. Evidence for reduced vascular phosphoinositide metabolism in gravid rats. *J. Am. Soc. Nephrol.* 1:487, 1990.
30. Colpoys M.C., Brinck-Johnsen T. and **Conrad K.P.** Cardiovascular effects of sex steroids: serial studies in chronically instrumented, conscious rats. *Clin. Exp. Hypertension B10*:217, 1991.
31. **Conrad K.P.**, Barrera S.A. and Schmidt V.M. Further evidence for attenuated myo-inositol (MI) uptake, phosphoinositide (PI) turnover and inositol phosphate (IP) production in vasculature of gravid rats. *Clin. Exp. Hypertension B10*: 113, 1991.

32. **Conrad K.P.** Russ. R.D. and Walker B.R. Baroreflex control of heart rate in conscious pregnant rats. *FASEB J* 5:A1114, 1991.
33. Whittemore S.L. and **Conrad K.P.** In vivo assessment of endothelium-derived relaxing factor (EDRF) activity during rat pregnancy. *FASEB J* 5:A392, 1991.
34. **Conrad K.P.** Low dosages of arginine derivatives potentiate pressor responsiveness of vasoconstrictors in conscious rats. Scientific Conference on Functional and Structural Mechanisms of Vascular control. January 29-February 1, 1992.
35. Gilson G.J., Mosher M.D. and **Conrad K.P.** Systemic hemodynamics and oxygen transport during pregnancy in chronically instrumented conscious rats. 39th Annual Meeting of the Society of Gynecologic Investigation, San Antonio, March 18-21, 1992.
36. **Conrad K.P.**, Joffe G.M., Kruszyna H., Kruszyna R., Rochelle L.G., Smith R.P., Chavez J.E. and Mosher M.D. Identification of increased nitric oxide biosynthesis during pregnancy in rats. *J. Am. Soc. Nephrol.* 3:542, 1992.
37. **Conrad K.P.**, Mosher M.D. and Del Valle G.O. Serum immunoreactive erythropoietin (iEPO) and red cell volume (RCV) during pregnancy in conscious rats. *J. Am. Soc. Nephrol.* 3:424, 1992.
38. Vill M., Dail W.G. and **Conrad K.P.** Trophoblasts are a possible source for the increased nitric oxide production of pregnancy: NADPH diaphorase staining. 40th Annual Meeting of the Society of Gynecologic Investigation, Toronto, April 1-3, 1993.
39. Roe T., Jaramillo C., McGee M. and **Conrad K.P.** Effects of plasma from gravid rats on cyclic guanosine 3', 5'-monophosphate (cGMP) production in RFL-6 cells. SACNAS Annual Conference, Albuquerque, NM, January 14-18, 1993.
40. Danielson L., Mosher M. and **Conrad K.P.** Effects of chronic inhibition of nitric oxide synthesis on renal hemodynamics in conscious virgin and gravid rats. 5th Annual Biomedical Sciences Graduate Student Research Day, March 4-5, 1993.
41. Gough S.R., Mosher M.D. and **Conrad K.P.** Metabolic clearance rate of recombinant human ¹²⁵I-erythropoietin in conscious pregnant rats. IXth Congress of the International Society for the Study of Hypertension in Pregnancy, Sidney, March 15-18, 1994.
42. Danielson L.A. and **Conrad K.P.** Role of nitric oxide in renal hyperfiltration and vasodilation during pregnancy in conscious, chronically instrumented rats. *J. Am. Soc. Nephrol.* 5:576, 1994.
43. **Conrad K.P.** and Davis A.K. Nitric oxide synthase activity in placentas from preeclamptic women. *J. Soc. Gynecol. Invest.* 2:291, 1995.
44. Nevils B.G. and **Conrad K.P.** Increased circulating levels of TNF- α in preeclampsia: a possible role for cytokines in the pathogenesis of the disease. *J. Soc. Gynecol. Invest.* 2:311, 1995.
45. Danielson L.A. and **Conrad K.P.** Nitric oxide mediates renal hyperfiltration and vasodilation during pregnancy in chronically instrumented, conscious rats. *J. Soc. Gynecol. Invest.* 2:192, 1995.
46. **Conrad K.P.** and Mosher M.D. Nitric oxide biosynthesis in normal and preeclamptic pregnancy--a preliminary report. *J. Am. Soc. Nephrol.* 6:657, 1995.
47. **Conrad K.P.**, Benyo D.F., Westerhausen-Larson A. and Miles T.M. Evidence for erythropoietin expression by human placenta. *J. Am. Soc. Nephrol.* 6:735, 1995.
48. **Conrad K.P.** Vasoactive mediators in normal pregnancy and preeclampsia. 13th International Congress of Nephrology, Madrid, July 2-6, 1995.
49. Benyo D.F., Miles T.M. and **Conrad K.P.** Tumor necrosis factor- α production by cultured villous explants from term placenta is stimulated by hypoxia. *J. Soc. Gynecol. Invest.* 3:237A, 1996.
50. **Conrad K.P.**, Benyo D.F., Westerhausen-Larson A. and Miles T.M. Expression of erythropoietin by the human placenta. *J. Soc. Gynecol. Invest.* 3:59A, 1996.
51. Benyo D.F., Miles T.M. and **Conrad K.P.** Production of interleukin-1 β and -6 by cultured villous explants from term placenta in response to hypoxia. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy, Seattle, August 4-8, 1996.
52. Prieto J.A., Benyo D.F., Miles T.M. and **Conrad K.P.** Human 'de novo' endothelium is activated by TNF- α concentrations relevant to preeclampsia. 10th World Congress of the International Society for the Study of Hypertension in Pregnancy, Seattle, August 4-8, 1996.
53. Danielson L.A. and **Conrad K.P.** Prostaglandins maintain renal vasodilation and hyperfiltration during chronic nitric oxide synthase blockade in conscious, pregnant rats. *J. Am. Soc. Nephrol.* 7:1579, 1996.

54. Benyo D.F., Miles T.M. and **Conrad K.P.** Cytokine production by cultured villous explants from term placenta in response to hypoxia. *Placenta* 17:A16, 1996.
55. Gandley R.E., **Conrad K.P.** and McLaughlin M.K. Nitric oxide regulates myogenic behavior in the renal resistance vasculature at mid-pregnancy in the rat. *J. Soc. Gynecol. Invest.* 3:100A, 1996.
56. Benyo D.F., Miles T.M. and **Conrad K.P.** Inflammatory cytokine production by human villous placental explants in response to hypoxia varies depending on gestational age. *J. Soc. Gynecol. Invest.* 4:95A, 1997.
57. **Conrad K.P.**, Miles T.M. and Benyo D.F. Evidence for expression of the erythropoietin receptor by trophoblast cells of the human placenta. *J. Soc. Gynecol. Invest.* 4:136A, 1997.
58. **Conrad K.P.**, Ogawa T., Nakanishi S. and Danielson L.A. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in conscious rats. *J. Am. Soc. Nephrol.* 8:A1505, 1997.
59. Gandley R.E., **Conrad K.P.** and McLaughlin M.K. Endothelin and nitric oxide regulate myogenic behavior in the renal resistance vasculature at mid-pregnancy in the rat. *J. Am. Soc. Nephrol.* 8:A1511, 1997.
60. Danielson L.A., Sherwood O.D. and **Conrad K.P.** Relaxin is a potent renal vasodilator in conscious rats. *J. Soc. Gynecol. Invest.* 5:146A, 1998.
61. Martin D. and **Conrad K.P.** Evidence for the expression of endothelial nitric oxide synthase by extravillous trophoblasts in the human placenta. *J. Soc. Gynecol. Invest.* 5:119A, 1998.
62. **Conrad K.P.**, Gandley R.E., Ogawa T., Nakanishi S. and Danielson L.A. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy. *FASEB J.* 12:A52, 1998.
63. Gandley R.E., **Conrad K.P.** and McLaughlin M.K. Endothelin and nitric oxide regulate myogenic behavior in the renal resistance vasculature at mid-pregnancy in the rat. *FASEB J.* 12:A99, 1998.
64. Danielson L.A., Sherwood O.D. and **Conrad K.P.** Relaxin mediates renal vasodilation and hyperfiltration in conscious rats. *J. Am. Soc. Nephrol.* 9:336A, 1998.
65. **Conrad K.P.**, Kerchner L.J., Smith R.P. and Mosher M.D. Plasma level and 24-hour urinary excretion of NOX and cGMP in normal pregnancy and preeclampsia: cross-sectional and serial studies in women on a NOX-reduced diet. *J. Soc. Gynecol. Invest.* 6:119, 1999.
66. Novak J., Ramirez R.J., **Conrad K.P.**, Gandley R.E. and McLaughlin M.K. Relaxin decreases vascular reactivity in mesenteric resistance arteries in the rat. *Exper. Biol.*, 13:A758, 1999.
67. Novak J., Ramirez R.J., **Conrad K.P.**, Gandley R.E. and McLaughlin M.K. Relaxin decreases vascular reactivity in mesenteric resistance arteries in the rat. *J. Soc. Gynecol. Invest.* 6:191A, 1999.
68. Benyo D.F., Agatista P. and **Conrad K.P.** Levels of inflammatory cytokines in normal term and preeclamptic placentas, and their regulation by oxygen. *J. Soc. Gynecol. Invest.* 7(Suppl.): 293A, 2000.
69. Rajakumar R.A. and **Conrad K.P.** Expression, ontogeny and regulation of hypoxia inducible transcription factors in the human placenta. *J. Soc. Gynecol. Invest.* 7(Suppl.):184A, 2000.
70. Rajakumar R.A., Schatzman C., Whitelock K.A. and **Conrad K.P.** Protein levels of hypoxia inducible transcription factor HIF-2 α , but not HIF-1 α or -1 β , are increased in the placenta during preeclampsia. *J. Soc. Gynecol. Invest.* 7(Suppl.): 287A, 2000.
71. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Endothelin mediates the nitric oxide-dependent renal vasodilation and hyperfiltration by relaxin. *J. Soc. Gynecol. Invest.* 7(Suppl.): 82A, 2000.
72. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Relaxin is a potent renal vasodilator in conscious male rats. *J. Soc. Gynecol. Invest.* 7(Suppl.): 250A, 2000.
73. Novak J., Miles T.M. and **Conrad K.P.** Levels of immunoreactive nitric oxide synthase isoforms in the rat kidney during pregnancy. *J. Soc. Gynecol. Invest.* 7(Suppl.): 250A, 2000.
74. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Endothelin mediates the nitric oxide-dependent renal vasodilation by relaxin. *FASEB J.* 14:137A, 2000.
75. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Relaxin is a potent renal vasodilator in conscious male rats. *FASEB J.* 14:138A, 2000.
76. Novak J., Ramirez R.J., Sherwood O.D. and **Conrad K.P.** Relaxin decreases myogenic reactivity in small renal arteries. In: *Relaxin 2000 3rd International Conference on Relaxin and Related Peptides.* Tregear G.W., Ivell R., Bathgath R.A., Wade J.D. (eds), in press.
77. Danielson L.A., Kerchner L.J. and **Conrad K.P.** Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats. *FASEB J.* 2000

78. Novak J., Danielson L.A., Kerchner L.J., Sherwood O.D., Ramirez R.J., Moalli P.A. and **Conrad K.P.** Relaxin (RLX) is the "elusive" renal vasodilator of pregnancy in conscious rats. *FASEB J.* 15 (No. 4): A148, 2001.
79. Danielson L.A., Novak J., Kerchner L.J., Sherwood O.D., Ramirez R.J., Moalli P.A. and **Conrad K.P.** Relaxin (RLX) is the "elusive" renal vasodilator of pregnancy in conscious rats. *J. Soc. Gynecol. Invest.* 8(1 Suppl): 266A, 2001.
80. Rajakumar A., Ketah D., Manderfield L., Daftary A.R., Harger G. and **Conrad K.P.** Evidence for compromised oxygen transduction in placentas from preeclamptic patients: A study of oxygen sensing and proteasomal degradation with reference to hypoxia inducible transcription factor-2 α protein expression. *J. Soc. Gynecol. Invest.* 8(1 Suppl): 53A, 2001.
81. Rajakumar A., **Conrad K.P.**, Gandley R.E., and Hubel C.A. Angiotensin II mediates nonhypoxic induction of hypoxia-inducible transcription factor-1 α in the human placenta. *J. Soc. Gynecol. Invest.* 9:80A, 2002.
82. Novak J., and **Conrad K.P.** Matrix metalloproteinase 2 mediates the reduced myogenic reactivity during pregnancy in relaxin-treated nonpregnant rats. *FASEB J.* 16:A474, 2002.
83. Powers R.W., Majors A.K., Kerchner L.J., and **Conrad K.P.** Renal handling of maternal homocysteine during normal pregnancy and preeclampsia. *Hypertension in Pregnancy.* 21:77, 2002.
84. Benyo D.F., and **Conrad K.P.** Circulating levels of interleukin-6 and tumor necrosis factor- α throughout pregnancy in women with a high risk to develop preeclampsia. *Hypertension in Pregnancy.* 21:98, 2002.
85. Hubel C.A., **Conrad K.P.**, Gandley R.E., Sims C., Dechend R., Homuth V., Luft F.C., and Rajakumar A. Angiotensin II mediates nonhypoxic induction of hypoxia-inducible transcription factor-1 α in the human placenta. *Hypertension in Pregnancy.* 21:115, 2002.
86. Rajakumar A., Doty K., Daftary A., Markovic N., and **Conrad K.P.** Expression of Von Hippel Lindau (pVHL) protein in placentas from normal pregnant (NP) women and women with preeclampsia. *Hypertension in Pregnancy.* 21:112, 2002.
87. Rajakumar A., Doty K., Daftary A., Harger G., and **Conrad K.P.** Villous explants from preeclamptic (PE) placentas show impaired downregulation of HIF proteins with oxygenation *in vitro*. *Hypertension in Pregnancy.* 21:12, 2002.
88. Jeyabalan A., Danielson L.A., Kerchner L.J. and **Conrad K.P.** Vascular matrix metalloproteinase(s) mediates renal vasodilation and hyperfiltration in relaxin-treated rats. *J. Soc. Gynecol. Invest.* 10(Suppl.): 198A, 2003
89. Kerchner L.J., Fisher M.C., and **Conrad K.P.** The pregnancy hormone relaxin upregulates matrix metalloproteinase-2 (MMP-2) in small renal arteries from rats. *J. Soc. Gynecol. Invest.* 10(Suppl.): 244A, 2003.
90. Novak J., Opett S.L. and **Conrad K.P.** Matrix metalloproteinase 2 mediates the reduced myogenic reactivity during pregnancy and in relaxin-treated nonpregnant rats. *J. Soc. Gynecol. Invest.* 10(Suppl.): 245A, 2003.
91. Rajakumar A., Brandon H.M., Daftary A., Ness R. and **Conrad K.P.** The hypoxia inducible transcription factor, HIF-1 α , overexpressed in preeclamptic placentas is capable of binding to the hypoxia response element. *J. Soc. Gynecol. Invest.* 10(Suppl.): 304A, 2003.
92. Debrah D.O., **Conrad K.P.**, and Shroff S.G. Effects of relaxin on systemic arterial properties in conscious nonpregnant rats. 11th Annual Cardiovascular Minority Research Supplement Awardee Session. Orlando, November 8, 2003.
93. Novak J., **Conrad K.P.** Small renal arteries isolated from ET_B receptor deficient rats fail to exhibit the normal maternal adaptation to pregnancy. *FASEB J* 18(5) Part I, abstract #205.32, 2004
94. **Conrad K.P.**, Parry L.J., Shroff S.G., Debrah D.O., Novak J. Evidence that relaxin is a vascular-derived, locally-acting relaxin and compliance factor. Fourth International Conference on Relaxin and Related Peptides, Jackson Hole, Wyoming 2004.
95. Kerchner L.J., Hanley-Yanez, K. Doty K.D., **Conrad K.P.** Endothelin Type-B Receptor (ET_B) Expression is Not Increased by Relaxin or Pregnancy in Rat Small Renal Arteries and Is Inconsistently or Minimally Regulated by Relaxin in Cultured Human Endothelial Cells. Fourth International Conference on Relaxin and Related Peptides, Jackson Hole, Wyoming 2004.

96. Smith M.C., Davison J.M., **Conrad K.P.**, Danielson L.A. The Renal Haemodynamic Effects of Relaxin (RLX) in Humans. Fourth International Conference on Relaxin and Related Peptides, Jackson Hole, WY 2004.
97. Smith M.C., Davison J.M., **Conrad K.P.**, Danielson L.A., Murdoch A. Is Relaxin (RLX) a Stimulus for Osmoregulatory Changes in Humans? Fourth International Conference on Relaxin and Related Peptides, Jackson Hole, WY 2004.
98. Jeyabalan A., Kerchner L.J., Fisher M., Doty K., **Conrad K.P.** Matrix metalloproteinase-2 protein is upregulated in small arteries from pregnant and relaxin-treated rats. Fourth International Conference on Relaxin & Related Peptides, Jackson Hole, WY 2004.
99. Debrah D.O., **Conrad K.P.**, Novak J., Danielson, L.A., Shroff S.G. Recombinant Human Relaxin (rhRLX) Modifies Systemic Arterial Properties in Conscious Rats Irrespective of Gender, but in a Biphasic Fashion. Presented at the Beckman Scholars Symposium in Irvine, Florida and at the Fourth International Conference on Relaxin and Related Peptides. Jackson Hole, Wyoming 2004.
100. Debrah D.O., **Conrad K.P.**, Novak J., Danielson, L.A., Shroff S.G. Recombinant Human Relaxin (rhRLX) Modifies Systemic Arterial Properties in Conscious Rats Irrespective of Gender, but in a Biphasic Fashion. Presented at the Beckman Scholars Symposium. Irvine, Florida, 2004.
101. Jeyabalan A., Kerchner L.J., Fisher M., Doty K., **Conrad K.P.** Expression of matrix metalloproteinase-2 protein is upregulated in small arteries from pregnant and relaxin-treated rats. Society of Gynecologic Investigation, Houston, TX, 2004.
102. Smith M.C., Murdoch A.P., **Conrad K.P.**, Danielson L.A., Hindhough A., Davison J.M. Is Relaxin necessary to establish a normal renal response in human pregnancy? J Obstet Gynaecol. 24 Suppl 1(Abstracts of the British Maternal and Fetal Medicine Society 9th Annual Conference. Glasgow, United Kingdom, 1-2 April 2004): p. S9-79.
103. Smith M.C., Davison J.M., **Conrad K.P.**, Danielson L.A., Murdoch A. Is Relaxin (RLX) responsible for gestational renal and osmoregulatory adaptation? 14th World Congress of the International Society for the Study of Hypertension in Pregnancy (ISSHP). November 14-17, 2004, Vienna, Austria. Hypertension in Pregnancy. 23 Suppl 1: p34 2004 Nov.
104. Jeyabalan A., Kerchner L.J., Fisher M., **Conrad K.P.** Matrix metalloproteinase-9 but not matrix metalloproteinase-2 activity is upregulated in small arteries from rats acutely treated with relaxin. J. Soc. Gynecol. Invest. 12 (2) Supplement: 157A, 2005.
105. Rajakumar A., Michael H.M., Daftary A, Ness R, **Conrad K.P.** The Proteasomal Inhibitor, Clasto-Lactacystin, Reverses the Defect in HIF-1 α Protein Degradation in Preeclamptic Placentas. J. Soc. Gynecol. Invest. 12 (2) Supplement: 363A, 2005.
106. **Conrad K.P.**, Kerchner L.J., Novak J., Hanley-Yanez K., and Doty K.D. Endothelin Type-B (ET_B) Receptor Expression Is Not Increased by Relaxin or Pregnancy In Rat Small Renal Arteries and Is Inconsistently or Minimally Regulated by Relaxin in Cultured Human Endothelial Cells. J. Soc. Gynecol. Invest. 12 (2) Supplement: 156A, 2005.
107. **Conrad K.P.**, Parry L.J., Shroff S.G., Debrah D.O., and Novak J. Evidence That Relaxin is a Vascular-Derived, Locally-Acting Relaxing and Compliance Factor. J. Soc. Gynecol. Invest. 12 (2) Supplement: 304A, 2005.
108. Smith M.C., Davison J.M., **Conrad K.P.**, Danielson L.A. The Renal Haemodynamic Effects of Relaxin (RLX) in Humans. J. Soc. Gynecol. Invest. 12 (2) Supplement: 282A, 2005.
109. Rajakumar AR, Markovic N, Ness R, **Conrad KP.** HIF- α proteins and downstream genes, Flt-1 and sFlt-1, in normal pregnant, preeclamptic and IUGR placentas. J. Soc. Gynecol. Invest. 13 (2) Supplement 229A, 2006.
110. Rajakumar A, Michael HM, Daftary A, Harger G, **Conrad KP.** Placentas from women with preeclampsia and intrauterine growth restriction exhibit deficient proteasomal activity. J. Soc. Gynecol. Invest. 13 (2) Supplement 286A, 2006.
111. Debrah DO, **Conrad KP**, Novak J., Matthews JM, Ramirez RJ, and Shroff SG. Relaxin is essential for systemic vasodilation and increased arterial compliance during early pregnancy in conscious rats. J. Soc. Gynecol. Invest. 13 (2) Supplement 189A, 2006.

112. Jeyabalan A., Novak J., Doty K.D., Matthews J., Fisher M.C., Kerchner L.J., and **Conrad K.P.** Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short term administration of relaxin. *Hypertension in Pregnancy*. 25 Supplement 1: 219, 2006.
113. Matthews JE, Rubin JP, Novak J, and **Conrad KP.** Vascular endothelial growth factor (VEGF) is a new player in the slow relaxin (Rlx) vasodilatory pathway. *Reproductive Sci.* 14(1 suppl.): 114A, 2007.
114. Matthews JE, Rubin JP, Novak J, and **Conrad KP.** Relaxin (Rlx) induces fast relaxation in some rat and human arteries mediated by PI3 kinase and nitric oxide. *Reproductive Sci.* 14(1 suppl.): 114A, 2007.
115. Novak J, Rubin JP, Matthews J and **Conrad KP.** Relaxin (Rlx) mediated fast relaxation of arteries through PI3 kinase and nitric oxide. *FASEB J.* 21:A1371, 2007.
116. Novak J, Rubin JP, Matthews J and **Conrad KP.** Vascular endothelial growth factor (VEGF) is a new player in the slow relaxin (Rlx) vasodilatory pathway. *FASEB J.* 21:A1371, 2007.
117. Debrah DO, Debrah JE, Shroff SG, and **Conrad KP.** Relaxin regulates arterial wall structure and composition. *Reproductive Sci.* 15 (1 suppl.): 217A, 2008.
118. Debrah JE, Agoulnik A, and **Conrad KP.** Changes in arterial function by chronic relaxin infusion are mediated by the leucine rich repeat G coupled Lgr7 receptor. *Reproductive Sci.* 15 (1 suppl.): 217A, 2008.
119. Danielson LE, Debrah JE, and **Conrad KP.** The role of human chorionic gonadotropin in maternal vasodilation of pregnancy. *Reproductive Sci.* 15 (1 suppl.): 218A, 2008.
120. Debrah DO, Debrah JE, Shroff SG, and **Conrad KP.** Relaxin-induced compositional and geometric remodeling of small renal arteries. 5th International Conference on Relaxin and Related Peptides, Hawaii, 2008.
121. Debrah JE, Agoulnik AA, and **Conrad KP.** Changes in arterial function by chronic relaxin infusion are mediated by the leucine rich repeat G coupled Lgr7/RFXP1 receptor. 5th International Conference on Relaxin and Related Peptides, Hawaii, 2008.
122. Segal MS, Sautina L, Beem E, and **Conrad KP.** Relaxin affects endothelial progenitor cell number and function. 5th International Conference on Relaxin and Related Peptides, Hawaii, 2008.
123. Debrah DO, Debrah JE, Sacks MS, **Conrad KP,** and Shroff SG. Determinants of relaxin-induced changes in passive compliance of small renal arteries: geometric vs. compositional remodeling. 5th International Conference on Relaxin and Related Peptides, Hawaii, 2008.
124. Debrah JE, McGuane JT, Novak J, Rubin JP, and **Conrad KP.** Vascular endothelial and placental growth factors: new players in the slow relaxin vasodilatory pathway. 5th International Conference on Relaxin and Related Peptides, Hawaii, 2008.
125. McGuane JT, Debrah JE, Novak J, Rubin PJ, and **Conrad KP.** Vascular endothelial and placental growth factors are new players in the “slow” relaxin vasodilatory pathway. XVI International Society for the Study of Hypertension in Pregnancy, Washington DC, 2008.
126. McGuane JT, Sautina L, Debrah JE, Segal MS, and **Conrad KP.** Mechanisms of relaxin-induced rapid arterial relaxation. *Reproductive Sci.* 16(3 Suppl.): 130A, 2009.
127. Jeyabalan A, Stewart D, McGonigal S, Powers RW, and **Conrad KP.** Low relaxin concentrations in the first trimester are associated with increased risk of developing preeclampsia. *Reproductive Sci.* 16(3 Suppl.): 101A, 2009.
128. Founds SA, Conley YP, Lyons-Weiler, JF, Jeyabalan A, Hogge WA, and **Conrad KP.** Altered Global Gene Expression in First Trimester Placentas of Women Destined for Preeclampsia. Annual International Society for Nurses in Genetics Annual Conference Conference, November 10, 2008.
129. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, and **Conrad KP.** Altered Global Gene Expression in First Trimester Placentas of Women Destined for Preeclampsia. Sixth Symposium on the Functional Genomics of Critical Illness and Injury, November 17, 2008, National Institutes of Health, Bethesda, Maryland.
130. Danielson LA, McGuane JT, Debrah JE, **Conrad KP.** Relaxin-induced renal vasodilation and hyperfiltration are mediated by vascular endothelial growth factor receptor(s) in chronically-instrumented, conscious rats. *Reproductive Sci.* 11: 357A, 2010.
131. Post Uiterweer ED, Herrera D, McGuane JT, Parry LJ, and **Conrad KP.** Relaxin stimulates trophoblast invasion in vitro. *Reproductive Sci.* 19:387A, 2012.

132. Parry LJ, Gooi JH, Vodstrcil LA, Richardson M, Jelinic M, Wlodek ME, **Conrad KP**, Tare M. Relaxin regulates maternal uterine artery adaptations to pregnancy. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
133. Segal MS, Sautina L, Diao YP, Agoulnik AI, Grant MB, McGuane JT, **Conrad KP**. Relaxin is a novel promoter of bone marrow derived endothelial cell mobilization and migration. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
134. **Conrad KP**, Danielson LA, Parry LJ, Shroff S, Novak J, Jeyabalan A, Davison JM, Segal MS, McGuane JT. Vascular actions and mechanisms of relaxin within and without pregnancy. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
135. Shroff SG, **Conrad KP**. Antifibrotic effects of relaxin: renal vascular wall mechanics. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
136. Post Uiterweer ED, Herrera D, McGuane JT, Parry LJ, **Conrad KP**. Relaxin increases trophoblast invasion in vitro. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
137. Soh YM, Tiwari A, Mahendroo M, **Conrad KP**, Parry LJ. Relaxin regulates hyaluronan synthesis and aquaporins in the cervix of late pregnant mice. 6th International Conference on Relaxin and Related Peptides, Florence, Italy, 2012.
138. Campo B, Post Uiterweer ED, **Conrad KP**. Developing novel therapeutics for preeclampsia. *Reproductive Sci.* 20:259A, 2013.
139. Rabaglino MB, Uiterweer EDP, **Conrad KP**. Endometrial antecedents of preeclampsia. *Reproductive Sci.* 21:395A, 2014.
140. Post Uiterweer ED, Koster MP, Jeyabalan A, Kuc S, Siljee J, **Conrad KP**, Franx A. First trimester serum relaxin concentration and prediction of early and late onset preeclampsia. *Reproductive Sci.* 21:394A, 2014.
141. Bartley J, Campo B, Hiebert L, **Conrad KP**. Proteasome inhibition increases soluble vascular endothelial growth factor (sFlt1) secretion from human trophoblast. *Reproductive Sci.* 21:178A, 2014.
142. **Conrad KP**, Segal MS, Keller-Wood M, Chi YY, Hamilton KK, Williams RS, Rhoton-Vlasak A, Nichols WW, Liu J. Evidence for Impaired Maternal Circulatory Adaptations In Pregnancies Conceived Using Donor Eggs. *Reproductive Sci.* 21:282A, 2014.
143. M. Belen Rabaglino, Emiel D. Post Uiterweer, Arun Jeyabalan, W. Allen Hogge, **Kirk P. Conrad**. A Systems Biology Approach Reveals Evidence for Defective Endometrial Maturation in Women Destined to Develop Preeclampsia (PE). *International Society for the Study of Hypertension in Pregnancy*. October 2014.
144. Woodward L, Rusmak M, Ramirez R, Huang Z, Lopez C, Agoulnik A, **Conrad KP**, Novak J. Vascular reactivity is altered in mice with a conditional knockout of relaxin receptor in endothelial cells. *FASEB J.* 28 Suppl 1:681.11, 2014.
145. Borja YY, Boudreaux RL, **Conrad KP**. Cholecystokinin expression and localization in human placenta. *Reproductive Sci.* 22:376A, 2015.
146. Kilar CR, Diao YP, Sautina L, Mohandas R, **Conrad KP**, Segal MS. Defining the mechanism of erythropoietin's vasoactive properties in resistance arteries. *FASEB J.* 30:(Suppl 1) Ib773, 2016.
147. Rabaglino MB, Post Uiterweer ED, **Conrad KP**. A bioinformatics approach shows significant overlap of molecular pathology in early preeclampsia with endometrial diseases. *ISCB Latin America*. Buenos Aires, Argentina, November 2016.
148. Petersen JW, Liu J, Chi Y-Y, Lingis MD, Williams RS, Rhoton-Vlasak A, Hamilton KA, Segal MS, **Conrad KP**. Comparison of multiple non-invasive methods of measuring cardiac output during pregnancy reveals marked heterogeneity in the magnitude of cardiac output change between women. **Reproductive Sci.**24:209A, 2017.
149. Rabaglino MB, Post Uiterweer ED, **Conrad KP**. Evidence for partial overlap of molecular etiology between preeclampsia and decidualization disorders. *Reproductive Sci.* 24:91A, 2017.
150. Kilar CR, Diao Y-P, Sautina L, Sekharan S, Keinan S, **Conrad KP**, Segal MS, Mohandas R. Activation of the heterodimeric erythropoietin/ β -common receptor impairs acetylcholine mediated vasodilation in mouse mesenteric arteries. *FASEB J.* 27(suppl. 1), 2017.
151. Von Versen-Hoeynck F, **Conrad KP**, Baker VL. Effect of corpora lutea number on serum electrolytes and creatinine in early pregnancy. *Fertility and Sterility* 108 (issue 3 suppl.);e379-e380, 2017.

152. Schaub AM, Chiu H-H, Chi Y-Y, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols AA, Segal MS, **Conrad KP**. Longitudinal changes in pulse wave velocity (PWV) during normal human pregnancy. *Reproductive Sci.* 25 (suppl. 1): 223A, 2018.
153. Rodriquez D, Mohandas R, , Chiu H-H, Chi Y-Y, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols AA, Segal MS, **Conrad KP**. Global arterial compliance (GAC) and wave reflections during normal human pregnancy. *Reproductive Sci.* 25 (suppl. 1): 223A, 2018.
154. Rabaglino MB, **Conrad KP**. A pathway driven approach suggest defective decidual NK cells in preeclampsia and endometrial disorders. *Reproductive Sci.* 25 (suppl. 1): 310A, 2018.
155. Schaub AM, Chiu H-H, Chi Y-Y, Lingis M, Williams RS, Rhoton-Vlasak A, Nichols AA, Wood CE, Sumners ES, Keller-Wood M, Segal MS, **Conrad KP**. Abnormal pulse wave velocities in women conceiving by assisted reproductive technology who lack a corpus luteum. 8th International Conference on Relaxin and Related Peptides 2018.
156. Von Versen-Hoyneck F, Chiu K-H, Chi YY, Fleischmann RR, Zhang W, Winn VD, Conrad KP, Baker VL. Absence of the corpus luteum increases the risk of preeclampsia. 8th International Conference on Relaxin and Related Peptides 2018.

PROFESSIONAL ACTIVITIES

TEACHING:

In Pittsburgh, I taught undergraduate, graduate and medical students at the University of Pittsburgh School of Medicine, as well as post-doctoral (Ph.D.) and clinical (M.D.) fellows, the latter from the Maternal-Fetal Medicine Division of the Department of Obstetrics, Gynecology, and Reproductive Sciences of the University of Pittsburgh School of Medicine. In addition, I participated actively in the mentoring and academic development of junior faculty members in the Department of Obstetrics, Gynecology, and Reproductive Sciences and other junior investigators at the Magee-Womens Research Institute.

Following are some highlights of my teaching efforts. For undergraduate students, I was involved in their scientific training during the summer months at the University of Pittsburgh. On average, we had two students per summer in the lab. I also directed (or co-directed with Jackie Novak, PhD) the College Summer Training Program. In addition, I trained local high school teachers and students in the laboratory during the summer, and hosted AP Biology from Seneca Valley High School in my laboratory for demonstrations (2002). My involvement with the medical students from the University of Pittsburgh School of Medicine was in the capacity of a facilitator in two tutorials on cardiovascular physiology every year, and as an advisor for a Journal Clubs involving the M.D./Ph.D. and straight M.D. students. Beginning January 2000, I began presenting a lecture titled "Maternal adaptations to pregnancy" to the second year medical students in the Reproductive and Developmental Biology course, and in 2002, a lecture titled "The Placenta" to graduate students at the University of Pittsburgh. Another major teaching commitment involved the research training of both Ph.D. and M.D. post-doctoral fellows (see below). Finally, I spend a considerable amount of time mentoring junior faculty and other trainees at the Magee-Womens Research Institute (see below).

Upon joining the Department of Physiology and Functional Genomics at the University of Florida, there was need for someone in the Department to teach Reproductive Physiology due to the retirement of Pushpa Kalra PhD. Therefore, I retooled, relearned and updated myself in this area and teach Reproductive Physiology to medical, dental and physician assistant students. In addition, I have been teaching Renal Physiology to Nephrology Fellows, Physician Assistant Students, and Undergraduate Students, and most recently (2016), Medical Students.

Courses

1984-1990	Renal Physiology, Dartmouth Medical School
1984-1990	Advanced Renal Physiology
1984-1990	Renal Pathophysiology
1990-1994	Renal and Cardiovascular Physiology, First Year Medical students, University of New Mexico School of Medicine
1990-1994	Maternal/Fetal Physiology, Maternal Fetal Medicine Fellows
1992-1994	Renal and Cardiovascular Physiology, First Year Graduate Students
1991	Cardiovascular Physiology, Physical Therapy students
1990-1994	Basic Science Training Program for Maternal Fetal Medicine Fellows
1991-1994	Minority Biomedical Research Support Program
1994	Cardiovascular Physiology, Undergraduate Students, University of Pittsburgh
1994-1999	Renal Physiology, Graduate Students, University of Pittsburgh School of Medicine
1994-2006	Cardiovascular Physiology, First Year Medical Students, University of Pittsburgh School of Medicine
1996, 1998, 2000	Core Lecture Series for Ob/Gyn Residents, Magee Womens Hospital
2000-2006	Reproductive and Developmental Biology Course, Second Year Medical Students, University of Pittsburgh School of Medicine
2002-2006	MSCMP 2730, Molecular Mechanisms of Tissue Growth and Repair, University of Pittsburgh School of Medicine
2002-2006	Journal Club for Second Year Medical or MD/PhD students, University of Pittsburgh School of Medicine (intermittent)

University of Florida College of Medicine

2006-present	GMS6410 Advanced Circulation Graduate Students
2007-2015	GMS6008 IDP Graduate Course
2007-2012	Reproductive Physiology, First Year Medical and Graduate Students
2009-2012	Section Director for Reproductive Physiology, First Year Medical and Graduate Students
2014-present	Reproductive Physiology, Second Year Medical Students
2007-present	Reproductive Physiology, Physician Assistant Students
2007-present	Advanced Renal Physiology Graduate Students
2008-present	Reproductive Physiology, Dentistry Students
2008-2011	Renal Physiology for Nephrology Fellows
2010-2015	Renal Physiology for Physicians Assistant Students
2012	Human Placenta and Trophoblast Invasion, MFM Fellows Conference
2012-present	Renal Physiology for Undergraduate Students
2013-present	Fundamentals of Physiology, Course Director of Endocrine Physiology, Distant Learning
2011-present	Advances in Hypertension Research
2013	Exploring the Etiology of Preeclampsia, MFM Fellows Conference
2014	Renal Hemodynamics, Nephrology Fellows Conference
2014	Corpus Luteal Contributions to Maternal Pregnancy Physiology and Outcomes, MFM Fellows Conference
2016-	Renal Physiology and Foundations Block (Body Fluid Compartments), First Year Medical Students

Undergraduate Education and High School

2002-2004	Dan O. Debrah (Bioengineering Undergraduate Student)
2003	Vitaly Chibisov (Seneca Valley High School Senior Project)
2003	Trent Emerick (College Summer Student)

Curriculum

2007	Christian Robles (College Summer Student)
2008	Belin Kassu (College Summer Student)
2009	Robert Boudreaux (College Summer Student)
2009-11	Diana Herrera (Undergraduate Student)
2012	Lindsey Hiebert (College Summer Student)
2012-2013	Bertha Campo (Undergraduate Student)
2013-2017	Yamilette Borja (Undergraduate Student)
2016-2017	Mark Beckworth (Undergraduate Student)
2017	Lucia Cabanela (Undergraduate Student)
2018	Vienna Madrid (Undergraduate Student)
2018	Cathleen Mestre (Undergraduate Student)

N.B. Although I have not been directly involved in their laboratory training, other personnel in my laboratory have hosted numerous high school and college students 1994-2006.

Predoctoral Trainees

1988-1991	Susan Whittemore (PhD Thesis)
1989	Peter Morganelli (Lab Rotation)
1992-1995	Lee Danielson (PhD Thesis)
1993-1994	Steven Gough (Lab Rotation)
2001,2003	Kerry Whitelock (Lab Rotations)
2001-2002	Eric Chen (Lab Rotation)
2004-2008	Dan O. Debrah (PhD Thesis co-sponsored with Sanjeev G. Shroff, PhD)
2005	Jonathan McGuane (Lab Rotation)
2010-13	Emiel D. Post Uiterweer, Student Master in Medicine, University of Maastricht (Research Electives)
2010-11	Tjeerd van der Veer, Medical Student, Erasmus MC University Medical Center (Research Elective)
2010-11	Anne Beelen, Student Master in Medicine, University of Maastricht (Research Elective)
2013-14	Karlijn Sax, Student Master in Medicine, University of Maastricht (Research Elective)
2013	Joanne Bartley, First Year Medical Student University of Florida (Summer Research Elective)
2017-8	Shedy Taher, Student Master in Medicine, University of Maastricht (Research Elective)

Postdoctoral Trainees

1987-1989	Marilyn Brandt, PhD
1990-1991	George Gilson, MD
1991-1992	Geraldo Del Valle, MD
1992-1993	Gary M. Joffe, MD
1993-1994	Magee Vill, MD
1995-1996	Jose Prieto, MD
1996-1999	Dibe Martin, MD
1996-1999	Robin Gandley, PhD (co-sponsored with M.K. McLaughlin, PhD)
1997-1999	Jacqueline Novak, PhD (co-sponsored with M.K. McLaughlin, PhD)
2001-2003	Arundhathi Jeyabalan, MD
2007-2011	Jonathan McGuane, PhD
2009-2013	Melissa Lingis, PhD
2013	Jill L. Seabrook, PhD
2013-2016	Oluseyi Ogunleye, MD
2017-present	Amelia Schaub, MD
2017-present	Claudia Rodriguez, MS
2017-present	Georgia Graham MD

High School Summer Teacher Training Program

1999-2001 Lisa Pugne, BS

Visiting Scientist

Laura J. Parry, PhD. Senior Lecturer in the Department of Zoology, University of Melbourne. September 2005; March/April, June/July 2007; May-July 2008; February-May 2010

Other

I served on the **Thesis Committees** of Kelly Griggs and Tom Resta, who received their Ph.D. degrees at the University of Vermont (1991) and the University of New Mexico (1995), respectively. I also served on the Ph.D. Thesis Committee of Andrea Witlin D.O., University of Texas Medical Branch at Galveston (2000-2002); Masters Degree Committee of Eric Chen, Department of Bioengineering, University of Pittsburgh (2002); PhD Thesis Committee of Yong He, Department of Bioengineering, University of Pittsburgh (2005-08); PhD Thesis Committee of Mark Cunningham, University of Florida (2010-14); PhD Thesis Committee of Wei Zhang Food Science and Human Nutrition, University of Florida (2012-2015); PhD Thesis Committee of Luis Siqueira Department of Animal Sciences, University of Florida (2013-2016); PhD Thesis Committee of Cody Kilar Department of Medicine, Division of Nephrology, University of Florida (2014-2017); PhD Thesis Committee of Miguel Zarate, Department of Physiology and Functional Genomics, University of Florida (2014-2017); PhD Thesis Committee of Emiel D. Post Uiterweer, University Medical Center, Utrecht Netherlands (2012-2015); PhD Committee Maria von Chamier, Department of Physiological Sciences, University of Florida (2013-); PhD Committee Kevin Yu Department of Physiology and Functional Genomics (2017-) Jessica Jackson, Department of Ob/Gyn, University of Florida (2016-18). Other visiting scientists from the United States and overseas, postdoctoral fellows, Ph.D. candidates, medical and undergraduate students have come through my laboratory over the years for shorter periods of time to acquire various research techniques or to gain exposure to bench research. Finally, I have contributed to the scientific career development and mentorship of junior faculty: Deborah Fairchild Benyo, Ph.D. (1995-1998), Leslie A. Danielson, PhD (1995-1998), Rosario Augustine Rajakumar, Ph.D. (1998-2006), Jacqueline Novak, Ph.D. (2000-2005), Arundhathi Jeyabalan, M.D. (2003-2006), Pamala Moalli, MD, PhD (2001-2006), Sandy Founds RN PhD (2005-2006), and Laura J. Parry PhD (2005-2012); Rajesh Mohandas (2014-present); Abdel Alli (2015-present); John Bromfield (2015-present); Dominick J. Lemas, Ph.D. (2015-present).

RESEARCH:

1. Extramural Funding

<u>Grant Number (Funded)</u>	<u>Grant Title</u>	<u>Role and Percentage of Effort</u>	<u>Years Inclusive</u>	<u>Source/Amount (approx. Direct Costs)</u>
National Kidney Foundation Fellowship		P.I.	1982-1983	NKF

Individual Fellowship NIH 1F32 HL06740		P.I.	1983-1984	NIH/NHLBI
New Hampshire Heart Assoc. Grant-in-Aid NH-84-G-06		P.I.	1984-1985	New Hampshire Heart Association
Physician Scientist Award K11 HD00662		P.I.	1985-1990	NIH/NICHD
R01 HL38076 (new grant)		P.I.	1987-1990	NIH/NHLBI
8th Mallinckrodt Scholar Award		P.I.	1988-1993	Mallinckrodt Co.
Flinn Newly Independent Investigator Award		P.I.	1991-1994	New Mexico Heart Association
March of Dimes Basic Science Grant		P.I.	1994-1996	March of Dimes
John R. McKune Charitable Trust	Placental cytokines and preeclampsia	P.I.	07/01/97- 06/30/99	John R. McKune Charitable Trust \$25,000
RCDA K04 HD 01098	Role of nitric oxide in trophoblast function and dysfunction	P.I. 80%	01/01/95- 12/31/99	NIH/NICHD \$300,000
R01 HD030325	Nitric oxide and maternal hemodynamics in pregnancy	P.I. 40%	12/01/93- 11/30/97	NIH/NICHD \$484,203
R01 HD030325 (competitive renewal)	Mechanisms of vasodilation in pregnancy	P.I. 30%	04/01/98- 03/31/02	NIH/NICHD \$837,222
2 P01 HD030367	Preeclampsia: convergence of fetal and maternal factors	P.I. of subproject #2 30%	12/01/96- 11/30/01	NIH/NICHD \$750,000
R01 HL056410	Regulation of placental cytokines by O ₂ , NO and CO	P.I. 20%	04/01/97- 03/31/03	NIH/NHLBI \$518,631
RO1 HL067937	Relaxin: the "elusive" vasodilator of pregnancy	P.I. 25%	08/01/01- 07/31/06 (with no cost ext.)	NIH/NHLBI \$550,000

RO1 DK063321 (competitive renewal of HD030325)	Mechanisms of vasodilation in pregnancy	P.I. 30%	08/01/02- 03/31/08 (with no cost ext.)	NIH/NIDDK \$738,000
PO1 HD030367 (competitive renewal)	Preeclampsia: convergence of fetal and maternal factors	P.I. of subproject #2 15%	02/01/02- 01/31/07	NIH/NICHD \$715,000
RO1 HL067937	Minority Undergraduate Student Research Supplement	PI Mentor to Dan O. Debrah	02/02/03- 12/31/03	\$7,096
Australian Research Council Linkage – International	Anti-aging role for relaxin in blood vessels	Co-PI 10%	2003-2005	\$40,763 (AU)
BIRCWH Faculty Development Award	Role of vascular gelatinase(s) in pregnancy and relaxin-mediated renal vasodilation and hyperfiltration	Mentor to Arun Jeyabalan, MD	07/01/03- 06/30/06	\$300,000
Health Research Formula Grant (Tobacco Settlement Act)	Relaxin: A vascular derived compliance and relaxing factor	PI 40%	01/01/05- 12/31/05	\$225,000
RO1 HL067937 (competitive renewal)	Endogenous relaxin regulates vascular function in nonpregnant females and males	P.I. 50%	04/01/06- 03/31/12 2 Yr. no cost ext.	NIH/NHLBI \$1,200,000
American Heart Association Grant in Aid 0855090E	New Players in the Relaxin Vasodilatory Pathway: Placental and Endothelial Growth Factors	PI 10%	07/01/08- 06/30/10	AHA \$165,000
Preeclampsia Foundation Vision Grant	Potential Therapeutic Role of Relaxin in Preeclampsia	PI & Mentor to Jonathan T. McGuane, PhD	2008-10 1 Yr. no cost ext.	PE Foundation \$25,000

Corthera Industry Contract	Comparison of the Biological Activities of Synthetic and Recombinant Human Relaxin	PI 10%	04/21/08-04/20/09	Corthera Inc. \$42,707
American Heart Association Fellowship	Potential Therapeutic Use of Relaxin in Preeclampsia	Mentor to JT McGuane, PhD	07/01/09-06/30/11	AHA \$91,592
R21 HL093605	Mechanisms of Renal Vasodilation by Relaxin	PI 5%	07/01/09-06/30/13 2 year NCE	NIH/NHLBI \$275,000
Center for UF Perinatal Research	Exploiting Novel Growth Factor-Trophoblast Interactions for Treatment of Preeclampsia and Intrauterine Growth Restriction	PI 5%	07/01/10-06/30/12	\$10,000
IFAS Innovation Funds, UF	Novel Regulators of Trophoblast Invasion	Co-PI 5%	10/01/10-09/30/11	\$50,000
UF & UF College of Medicine Bridge Funds	Corpus Luteal Contribution to Maternal Pregnancy Physiology and Outcomes in ART	PD 5%	01/01/10-12/31/11	\$100,000
PO1 HD065647-01A1	Corpus Luteal Contribution to Maternal Pregnancy Physiology and Outcomes in ART	PD 50%	09/27/11-02/28/19 (NCEs)	NIH/NICHD \$4,600,756

UF College of Medicine Matching Funds	Physiology and Outcomes in ART	PD 0%	09/27/11- 06/30/16	\$250,000
Gatorade Seed Funds	Potential Therapeutic Role of Relaxin in Bone Fracture Repair	Co-PI 5%	07/01/12- 06/30/14	\$60,000
Florida Department of Health Ester King Research Program	Vascular effects of relaxin receptor agonists	Co-I 5%	07/01/13- 6/30/14	\$33,238
Novartis CRLX030AUSNC06T	Unveiling Novel Signaling Mechanisms of Serelaxin in Vasculature	PI 10%	05/15/14- 12/31/17 (NCE)	\$164,900
US DOD Discovery Award	Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects	PI 7.5%	09/01/15 1/19/19 (NCE)	\$145,094
UF College of Medicine Bridge Funds	Endometrial Antecedents of Preeclampsia	PI 5%	07/01/14- open	\$50,000
UF College of Medicine Bridge Funds	Long-term Consequences of ART on the Physiology and Health of Offspring	PI	02/01/17- open	\$50,000

2. Invited Seminars and Lectures

Local

1. Seminars presented to the Departments of Physiology and Biochemistry of the University of New Mexico School of Medicine, and to Lovelace Medical Foundation, 1990-94.
2. Nitric oxide biosynthesis during pregnancy: implication for circulatory changes. Obstetrics and Gynecology Grand Rounds. University of New Mexico School of Medicine, May 1994.
3. Seminars presented to the Department of Physiology and Cell Biology, Department of Medicine-Renal-Electrolyte Division, and the Center for Clinical Pharmacology at the University of Pittsburgh, 1994-95.
4. Control of renal hemodynamics and glomerular filtration during pregnancy. Pittsburgh Smooth Muscle Group Meeting. Pittsburgh, July 1999.
5. Mechanisms of vasodilation in pregnancy. Center for Clinical Pharmacology Seminar Series. University of Pittsburgh School of Medicine. Pittsburgh, 2001.
6. Relaxin: new perspectives on an old hormone. Grand Rounds. Obstetrics/Gynecology and Reproductive Sciences. Magee-Womens Hospital and University of Pittsburgh School of Medicine. Pittsburgh, February 2001.
7. The emerging role of relaxin in renal and cardiovascular function. Research Seminar. Division of Nephrology. University of Pittsburgh School of Medicine. Pittsburgh, October 2003.
8. Placental hypoxia in pathological pregnancies: Hypoxia inducible transcription factors & regulated genes. Research Seminar presented to the Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, October 2006.
9. Mechanisms for renal and systemic hemodynamic changes during normal pregnancy: Implications for preeclampsia. Nephrology Research Seminar. University of Florida College of Medicine, Gainesville, October 2006.
10. Maternal vascular adaptations to pregnancy—hormonal and molecular mechanisms, and therapeutic implications. Reproductive and Perinatal Biology Research Seminar. University of Florida, Gainesville, February 2008.
11. Avant-Garde ART and Preeclampsia. Department of Physiology and Functional Genomics Seminar Series. Gainesville, FL November 2010.
12. Vascular Actions and Mechanisms of Relaxin. University of Florida Cardiology Grand Rounds. Gainesville, FL, February 2012.
13. The Challenge and Thrill of Translating Fundamental Biomedical Discoveries to Humans. Presented to the MD/PhD Program Director Selection Committee, UF Faculty and Students. February 2013.
14. Hemodynamic Antecedents of Preeclampsia. Reproductive and Perinatal Biology Research Seminar. University of Florida. October 2013.
15. Relaxin and the Kidney. Renal Grand Rounds. University of Florida College of Medicine, Division of Nephrology. November 2013.
16. Vascular Actions, Mechanisms and Therapeutic Potential of Relaxin. Physiology and Functional Genomics Seminar Series. University of Florida College of Medicine. December 2013.
17. Endometrial Antecedents of Preeclampsia. Reproductive and Perinatal Biology Research Seminar. University of Florida. February 2014.
18. Maybe it's the soil and not the seed: rethinking the genesis of placental syndromes. Physiology and Functional Genomics Seminar Series. University of Florida College of Medicine. November 2014.
19. It Takes a Good Soil To Grow a Seed: Rethinking the Genesis of Preeclampsia. Renal Grand Rounds. University of Florida College of Medicine. June 2015.
20. In Addition To "Seed", Should We Also Be Considering "Soil" In The Genesis Of Preeclampsia? Department of Physiology and Functional Genomics Seminar Series. University of Florida. November 06, 2017.
21. Maternal Physiology and Obstetrical Outcome After In Vitro Fertilization: New Perspectives and More Questions. Reproductive and Perinatal Biology Research Seminar. University of Florida. October 31, 2018.

National

1. Possible mechanisms for changes in renal hemodynamics during pregnancy: studies from animal models. International Symposium on Renal Function and Disease in Pregnancy. Chicago, September 1986.
2. Obstetrics Grand Rounds and Research Seminar. University of Vermont College of Medicine. Burlington, April 1988.
3. Endothelial effects on vascular function. Workshop on Maternal Cardiovascular Physiology and Pathophysiology. St. Louis, March 1990.
4. Alterations in vascular smooth muscle receptor signaling. Postgraduate Seminar: Cardiovascular Alterations in Pregnancy. 64th Annual meeting of the American Heart Association. Anaheim, November 1991.
5. Influence of oxytocin on renal hemodynamics and sodium excretion. Fifth International Conference on the Neurohypophysis. Hanover, July 1992.
6. Nitric oxide and pregnancy. Physiology Seminar. Bowman Gray School of Medicine. Winston-Salem, November 1993.
7. Nitric oxide biosynthesis during pregnancy: implications for circulatory changes. Symposium on Cardiovascular Regulation during Pregnancy. Experimental Biology. Anaheim, April 1994.
8. Nitric oxide biosynthesis during pregnancy: implications for circulatory changes. Physiology Seminar. West Virginia University Health Sciences Center. Morgantown, August 1994.
9. Trophoblast and endothelial function in pregnancy and preeclampsia: implications for circulatory changes. Symposium on Effects of Hormones on Cardiovascular Function: Implications for Women's Health. Experimental Biology. Atlanta, April 1995.
10. Nitric oxide biosynthesis during normal pregnancy and preeclampsia: implications for circulatory changes. Obstetrics and Gynecology Grand Rounds. University of Tennessee at Memphis. September 1996.
11. Nitric oxide biosynthesis during normal pregnancy and preeclampsia: implications for circulatory changes. Department of Physiology and Biophysics, University of Mississippi School of Medicine. Jackson, December 1996.
12. Obstetrics and Gynecology Ground Rounds. Placental cytokines and the pathogenesis of preeclampsia. University of Mississippi School of Medicine. Jackson, December 1996.
13. North American Trophoblast Meeting. Regulation of placental cytokine production by hypoxia. San Diego, March 1996.
14. Endothelin mediates renal vasodilation and hyperfiltration in conscious pregnant rats. No Name Society. Madison, May 1997.
15. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. Bicentennial Anniversary Lecture, Department of Physiology, Dartmouth Medical School. Hanover, June 1997.
16. The role of cytokines in the pathogenesis of preeclampsia. Bicentennial Anniversary Lecture, Obstetrics and Gynecology Grand Rounds. Dartmouth Medical School. Hanover, June 1997.
17. Mediators of renal vasodilation and hyperfiltration during pregnancy. FASEB Summer Research Conference. Perinatal regulation of the cardiovascular system. Copper Mountain, August 1997.
18. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy. Smith Kline and Beecham, King of Prussia, February 1998.
19. Control of renal hemodynamics and glomerular filtration during pregnancy. Perinatal Research Society. Park City, September 1998.
20. Placental trophoblast and vascular endothelial function in normal pregnancy and preeclampsia: Recent advances. A lecture in the series titled "The Cellular and Molecular Basis of Disease." University of New Mexico School of Medicine, Albuquerque, September 1998.
21. Expression and ontogeny of hypoxia inducible transcription factors in the human placenta. Tox Talks. Mill Valley, June 1999.
22. The elusive renal vasodilator of pregnancy. No Name Society. Winston-Salem, October 1999.
23. Expression, ontogeny and regulation of hypoxia inducible transcription factors in the human placenta. FASEB Summer Research Conference. Perinatal regulation of the cardiovascular system. Copper Mountain, June 2000.
24. Relaxin is a potent renal vasodilator in conscious rats. Connetics Corp., Palo Alto, April 2000.

25. Relaxin: new perspectives on an old hormone. Nephrology Expert Panel Meeting. Connetics Corp. Palo Alto, February 2001.
26. Relaxin: new perspectives on an old hormone. Research Seminar. Obstetrics and Gynecology. University of Texas Medical Branch at Galveston. Galveston, May 2001.
27. Relaxin: New perspectives on an old hormone. Department of Molecular and Integrative Physiology and the Center for Reproductive Biology. University of Illinois, Urbana-Champaign, September 2002.
28. Relaxin: New perspectives on an old hormone. Satellite Meeting – Fetal Physiology. 50th Annual Meeting of the Society for Gynecological Investigation. Washington, March 2003.
29. Hypoxia inducible transcription factors and preeclampsia. Symposium. New perspectives on preeclampsia. 50th Annual Meeting of the Society for Gynecological Investigation. Washington, March 2003.
30. Novel mechanisms in preeclampsia. Symposium. Role of inflammatory cytokines. 36th Annual Meeting of the American Society of Nephrology. San Diego, November 2003.
31. Mechanisms of maternal renal and cardiovascular adaptations to pregnancy. FASEB Summer Research Conference. Molecular and Cellular Signaling in the Perinatal Cardiovascular System. Tucson, August 2004.
32. Evidence that relaxin is a vascular-derived, locally-acting relaxing and compliance factor. Fourth International Conference on Relaxin and Related Peptides. Jackson Hole, September 2004.
33. Evidence that relaxin is a vascular-derived, locally-acting relaxing and compliance factor. No Name Society, Amelia Island, FL November 2004.
34. More on the vascular action of relaxin. Ob/Gyn Grand Rounds, Burlington, November 2004.
35. Vascular actions of relaxin. Research Seminar presented to the Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, March 2005.
36. Factors that regulate renal function in pregnancy. IUPS Satellite Symposium. Perinatal environment, programming and postnatal consequences. San Diego, March 2005.
37. Placental hypoxia inducible transcription factors in normal and pathological pregnancies. Research Seminar presented to the Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, August 2005.
38. Factors that regulate vascular function during pregnancy and beyond... Medical Ground Rounds. University of Colorado Health Sciences Center. Denver, October 2005.
39. Factors that regulate vascular function during pregnancy and beyond... Perinatal Biology Research Seminar, Loma Linda University, Loma Linda, February 2006.
40. Placental hypoxia in pathological pregnancies: Hypoxia-inducible transcription factors & regulated genes. No Name Society. Bowman, ND, September 2006.
41. Placental hypoxia in pathological pregnancies: Hypoxia-inducible transcription factors & regulated genes. NIH Workshop: Preeclampsia-A Pressing Problem. Bolger Center, Potomac, September 2006.
42. Vascular Adaptations to Pregnancy. Aspen Perinatal Biology Symposium. Given Institute. Aspen, August 2007.
43. In search of the elusive vasodepressor agents of pregnancy. 5th International Conference on Relaxin and Related Peptides 2008. Maui, May 2008.
44. Relaxin: The elusive vasodilatory of pregnancy. Lilly Research Seminar. Indianapolis, September 2008.
45. Vascular gelatinase is vasodilatory in normal pregnancy. XVI International Society for the Study of Hypertension in Pregnancy. Washington DC, September 2008.
46. VEGF and PIGF: New players in the relaxin slow vasodilatory pathway. No Name Society. Lake Arrowhead CA, January 2009.
47. The contribution of relaxin to circulatory adaptations of pregnancy. American Society of Reproductive Immunology. Orlando FL, June 2009.
48. Avant-Garde ART and Preeclampsia. Tox Talks. Mill Valley CA, June 2009.
49. Maternal vasodilation in pregnancy: The emerging role of relaxin. Ernest H. Starling Distinguished Lectureship of the American Physiological Society Water & Electrolyte Homeostasis Section. Anaheim CA, April 2010.
50. Maternal vasodilation in pregnancy: The emerging role of relaxin. Magee Womens Research Institute Research Seminar. Pittsburgh, May 2010.
51. Pregnancy and relaxin: Vasodilatory responses and mechanisms. Gordon Research Conference. Biddeford, ME, August 2010.

52. Pregnancy and relaxin: Vasodilatory responses and mechanisms. Aspen Perinatal Conference. Aspen, CO, August 2010.
53. Unveiling the vasodilatory actions and mechanisms of relaxin. Lilley Lecturer. Perinatal Research Society. Avon, CO, September 2010.
54. Maternal Vasodilation in Pregnancy: The Emerging Role of Relaxin. Department of Animal Science, Texas A&M University. College Station TX, February 2011.
55. Pregnancy and Relaxin: Vasodilatory Responses and Mechanisms. SGI Mini Symposium: Cardiovascular Adaptation to Pregnancy in Health and Disease. Miami, March 2011.
56. The Remarkable Vasodilatory Response to Pregnancy: Mechanisms, Implications and Spin-Offs. Fetal/Maternal Physiology Satellite Symposium. Miami, March 2011.
57. Corpus Luteal Contribution to Maternal Pregnancy Physiology and Outcomes. NICHD Directors Meeting. Rockville MD, May 2012.
58. Corpus Luteal Orchestration of Maternal Hemodynamics and Uterine Adaptations during the Luteal/Secretory Phase and Early Pregnancy. No Name Society. Banff, CA. October 2012.
59. Implications of Pregnancy Adaptations for Cardiovascular Medicine. Distinguished Seminar Series. Florida International University. Miami, FL. December 2012.
60. Corpus Luteal Contribution to Maternal Pregnancy Physiology and Outcome. Oregon Regional National Primate Center. Beaverton, OR. February 2013.
61. The Challenge and Thrill of Translating Fundamental Discoveries in Perinatal Biology to Women. Ob/Gyn Ground Rounds. University of Missouri, Columbia, MO. April 2013.
62. Exploring the Etiology of Preeclampsia. Tox Talks. Mill Valley, CA. June 2013.
63. Corpus Luteal Contributions to Maternal Pregnancy Physiology and Outcomes in ART. No Name Society Meeting. October 2013.
64. The Emerging Role of Relaxin in Maternal Vasodilation of Pregnancy: Implications for Cardiovascular Medicine. Microvasculature in Inflammatory Disorders Seminar Series. Department of Pathology, University of Texas Medical Branch. Galveston TX. January 2014.
65. The Cardiovascular Hormone, Relaxin: A Long Journey from Pregnancy to Potential Therapeutic. Novartis. East Hanover, NJ. April 2014.
66. A Systems Biology Approach Reveals Evidence for Defective Endometrial Maturation in Women Destined to Develop Preeclampsia. No Name Society Meeting. Shelburne VT 2014.
67. Potential Therapeutic Use of Relaxin in Preeclampsia. International Society for the Study of Hypertension in Pregnancy. New Orleans, LA. October 2014.
68. The Cardiovascular Hormone, Relaxin: A Long Journey from Pregnancy to Potential Therapeutic. 14th Annual McGowan Retreat. University of Pittsburgh. Nemaquin Woods Resort, PA. March 2015.
69. Hemodynamic Effects of Relaxin in Pregnancy and Beyond. Symposium on New Roles for Relaxin in Health and Disease. Endocrine Society Meeting. Boston, MA. April 2016.
70. Relaxin: A Long Journey from Pregnancy to Potential Therapeutic. Frontiers in Biomedical Research. North Dakota State University. Fargo, ND. June 3-4, 2016.
71. Does suboptimal decidualization contribute to impaired placentation in preeclampsia? No Name Society. Estes Park, CO. October 19-23, 2016.
72. Dysregulated (pre)decidualization in the genesis of preeclampsia. ToxTalk. Mill Valley, CA. June 24-28, 2017.
73. Emerging role for dysregulated decidualization in the genesis of preeclampsia. No Name Society. Tampa, FL. October 25-29, 2017.
74. Relaxin: A long journey from pregnancy to potential therapeutic. Department of Pharmacology Seminar Series. University of Vermont, Burlington. November 16, 2017.
75. Emerging role for dysregulated decidualization in the genesis of preeclampsia. SRI Mini-symposium: Endometrial antecedents of adverse pregnancy outcomes. San Diego, CA. March 08, 2018.
76. Prepregnant and periconceptional contributors to preeclampsia etiology. Predicting, Preventing and Treating Preeclampsia. Conference sponsored by NHLBI and NICHD. May 21-22, 2018.
77. Maternal Physiology and Obstetrical Outcome After In Vitro Fertilization: New Perspectives and More Questions. Ob/Gyn Grand Rounds. University of Vermont. Burlington, VT. October 16, 2018.

78. Endometrial Receptivity and Development of Preeclampsia. Joint MFM and REI Fellows Conference. University of Vermont. Burlington, VT. October 17, 2018.
79. Endometrial Antecedents of Preeclampsia. Preeclampsia Symposium. Perinatal Research Branch, NICHD. Wayne State University. Detroit, MI. October 29, 2018.
80. Pregnancy Physiology and Outcome in Women Conceiving by IVF in the Absence of a Corpus Luteum. Perinatal Research Branch, NICHD. Wayne State University. Detroit, MI. October 29, 2018.
81. Enigmatic Sequelae of IVF. No Name Society. Astoria, OR. November 06-09, 2018.

International

1. Placental nitric oxide synthase. Endocrinology Grand Rounds. John Hunter Hospital. Newcastle, N.S.W., Australia, March 1994.
2. Vasoactive mediators in normal pregnancy and preeclampsia. Symposium on pathophysiology of the vessel wall in pregnancy. XIII International Congress of Nephrology. Madrid, July 1995.
3. The renal circulation in normal pregnancy and preeclampsia. Perinatal Research Centre. University of Alberta, Edmonton, September 1999.
4. Expression, ontogeny and regulation of hypoxia inducible transcription factors in the human placenta. Perinatal Research Centre, University of Alberta, Edmonton, September 1999.
5. Is relaxin the "elusive" renal vasodilator of pregnancy? Third International Conference on Relaxin & Related Peptides. Broome, Western Australia, October 2000.
6. Hypoxia-inducible transcription factors in the human placenta. International Society for the Study of Hypertension in Pregnancy Workshop: Oxygen sensing and trophoblast invasion. Toronto, June 2002.
7. Relaxin: New perspectives on an old hormone. Symposium. A new era in relaxin research: therapeutic potentials. The Australian Health & Medical Research Congress. Melbourne, November 2002.
8. Mechanisms of maternal vasodilation pregnancy. Howard Florey Research Institute, Melbourne, November 2002.
9. More on the vascular action of relaxin. Research Seminars presented to the Department of Zoology, University of Melbourne; Baker Research Institute, Melbourne; Department of Physiology and Pharmacology, Monash University; Department of Ob/Gyn, Adelaide, Australia. January-June 2004.
10. International Society for the Study of Hypertension in Pregnancy. Vascular adaptations to pregnancy. Lisbon, July 2-5, 2006
11. Relaxin: Vasodilatory Responses and Mechanisms. Novartis Inc. Paris & Basel, September 2011.
12. Role of Relaxin in Maternal Hemodynamic and Endometrial Adaptations Before and During Early Pregnancy. 6th International Conference on Relaxin and Related Peptides. Florence Italy, October 2012.
13. Vascular Actions and Mechanisms of Relaxin Within and Without Pregnancy. Dutch Heart Foundation Lecture. Utrecht, Netherlands. October 2012.
14. Hormonal and Vascular Mechanisms of Circulatory Dilatation in Pregnancy. Symposium: Molecular Determinants of Renal Function. Regensburg, Germany. July 2013.
15. A Systems Biology Approach Reveals Evidence for Defective Endometrial Maturation in Women Destined to Develop Preeclampsia. Eurotox. Oxford UK. August/September 2014.
16. It Takes a Good Soil To Grow a Seed: Rethinking the Genesis of Preeclampsia. NEDWEP Symposium: Immunovascular Adaptations In Early Pregnancy and Long Term Consequences for Maternal Cardiovascular Health. University of Utrecht. June 2015.
17. Overview of Relaxin's Vascular Actions. 7th International Conference on Relaxin and Related Peptides. Kuching Malaysia, September 2015.
18. Potential Therapeutic Role of Relaxin-2 in Accelerating Bone Healing. 7th International Conference on Relaxin and Related Peptides. Kuching Malaysia, September 2015.
19. Consequences of Assisted Reproductive Technologies on the Physiology and Health of Offspring. No Name Society. Nassau, Bahamas. November 2015.
20. In Addition to "Seed", Should We Also Be Considering "Soil" in the Genesis of Preeclampsia? CoLab Meeting. Oxford, UK. August 29-September 01, 2016.

21. Does Suboptimal Decidualization Contribute to Impaired Placentation in Preeclampsia? Eurotox. Oxford, UK. September 01-03, 2016.
22. Abnormal pulse wave velocities in women conceiving by assisted reproductive technology who lack a corpus luteum. Relaxin and Related Peptides 2018. Cabo San Lucas, Mexico. May 6-10, 2018.

3. Other Research Related Activities

Journal Refereeing

American Journal of Obstetrics and Gynecology
American Journal of Physiology
American Journal of Hypertension
Biology of Reproduction
Circulation
Endocrinology
European Heart Journal
Hypertension in Pregnancy
Hypertension
Journal of Applied Physiology
Journal of Clinical Endocrinology and Metabolism
Obstetrics and Gynecology
New England Journal of Medicine
Pediatric Research
Placenta
Reproductive Sciences
Nature Reviews
Science (and sister Journals)
Journal of Clinical Investigation
Journal of Clinical Investigation Insight
Molecular Reproductive Endocrinology

Editorial Board

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 1996 - 2007.
American Journal of Physiology: Endocrinology and Metabolism. 2007-2016.

LIST OF ACTIVE RESEARCH INTERESTS:

The first area of research involves elucidation of the mechanisms underlying the remarkable vasodilation and increased arterial compliance during normal pregnancy with emphasis on the hormone relaxin, the relaxin receptor RXFP1, and target tissues including the endothelium, vascular smooth muscle and renal mesangium. The second deals with the potential therapeutic benefit of relaxin in bone fracture healing. The third area of scientific inquiry is the investigation of maternal systemic and uteroplacental circulatory adaptations to pregnancy in women who conceive by assisted reproductive technologies (ART). The fourth relates to the potential contribution of dysregulated decidualization before and during early pregnancy in the genesis of preeclampsia. Finally, a new area of research is the investigation of the long-term consequences of ART on the physiology and health of offspring.

SERVICE:

1. University and Medical School

1990-1994	OB/GYN Research Committee, University of New Mexico School of Medicine
1991-1994	Clinical Research Center Advisory Committee, University of New Mexico School of Medicine
1991-1993	Organizer of the Cardiovascular Journal Club and Seminar Series, University of New Mexico School of Medicine
1996-2000	Magee-Womens Hospital CRC Use Committee, University of Pittsburgh School of Medicine
1996-2006	Steering Committee, Magee-Womens Research Institute, University of Pittsburgh School of Medicine
1996-2006	Executive Committee for PO1 HD30367, Magee-Women Research Institute, University of Pittsburgh School of Medicine
1996-2006	Clinical Data Core Committee for PO1 HD30367, Magee-Womens Research Institute, University of Pittsburgh School of Medicine
1995, 1998, 2000, 2002	Faculty Handbook, Magee-Womens Research Institute, University of Pittsburgh School of Medicine
1997-2006	Interviewer, Maternal Fetal Medicine Fellowship Program, Magee-Womens Hospital, University of Pittsburgh School of Medicine
1998-2006	Postdoctoral Fellowship Committee, Magee-Womens Research Institute, University of Pittsburgh School of Medicine
1998-2006	Organizer of the Cardiovascular, Renal and Placental Journal Club, Magee-Womens Research Institute, University of Pittsburgh School of Medicine
2000-2005	Co-Director, Undergraduate Student Summer Program
2006	Director, Undergraduate Student Summer Program
2000-2004	WRHRCDC Scholar Advisory Committee and Leadership Team (Associate Director for Minority Recruitment), Magee-Womens Hospital, University of Pittsburgh School of Medicine
2002-2006	Advisory Committee and Leadership Team (Director of Basic Science) for the BIRCWH Program, University of Pittsburgh School of Medicine
2005	One of 4 members of a Task Force to interview all Ob/Gyn and Reproductive Sciences junior faculty at the University of Pittsburgh for review of promotions and tenure rules and procedures
2008-present	Interviewer, Maternal Fetal Medicine Fellowship Program, Department of Ob/Gyn, University of Florida College of Medicine
2007-2018	Organizer of the Reproductive and Perinatal Biology Research Program Seminar Series, University of Florida
2009-present	Steering Committee, Center for Perinatal Outcomes Research, University of Florida
2011-present	Organizer of the Work In Progress Conference for the Reproductive and Perinatal Biology Research Program, University of Florida
2013-present	University of Florida College of Medicine MD/PhD Advisory Committee Member

2. National and International

Extramural Grant Reviewing

National Institute of Diabetes and Digestive and Kidney Disease, Site Visit Team Member: January and November 1993.

National Institutes of Health, General Clinical Research Centers, Site Visit Team Member: April 1994.

Medical Research Council (UK), Ad hoc reviewer: 1994.
National Institutes of Health, Human Embryology and Development Study Section, Special Reviewer: October 1994, March 1996.
The Wellcome Trust (UK), Ad hoc reviewer: 1995, 2001, 2002, 2003 (twice).
American Heart Association, Reviewer for Grant-in-Aid proposals: February 1996.
National Institute of Child Health and Human Development, Site Visit Team Member: September 1997.
Tommy's Campaign (UK), Ad hoc reviewer: 1997.
Alberta Heritage Foundation for Medical Research, Ad hoc reviewer: 1998.
Action Research (UK), Ad hoc reviewer: 1999.
Member, NIH Human Embryology and Development Study Section-1: 2000-2003.
Israel Science Foundation, Ad hoc reviewer: 2000, 2002.
BBSRC, Ad hoc reviewer: 2003.
John Sealy Memorial Endowment Fund for Biomedical Research, Ad hoc reviewer: 2003, 2005, 2006.
NHMRC, Australia, Ad hoc reviewer: 2004, 2005.
Nova Scotia Health Research Foundation, Ad hoc reviewer, 2005, 2006.
BSF United States Israel Binational Science Foundation, Ad hoc reviewer, 2006.
MRC UK, Ad hoc reviewer, 2007.
NIH, Special Emphasis Panel, 2010.
NIH, Special Emphasis Panel, 2012.
Israel Science Foundation, Ad hoc reviewer, 2012.
Sparks for Children's Health UK, Ad hoc reviewer, 2012
NIH, Special Emphasis Panel, January 2013
Wellbeing May 2014
NIH, Special Emphasis Panel, July 2014
NIH Ad Hoc Reviewer Pregnancy Neonatology Study Section, October 2015
Chemical Sciences of the Netherlands Organisation for Scientific Research. Building Blocks of Life 2016, June 2016.
NIH Aging Systems and Geriatrics Study Section. Expert Outside Reviewer. February 2016.
Foundation Privee des Hopitaux Universitaires de Geneve, April 2017
Geneva University Hospitals and Faculty of Medicine Research Foundation S13, April 2018
\$1 Million Magee Prize October 2018

Other

Co-chairperson (with Lori Woods PhD), FASEB Summer Research Conference, Perinatal regulation of the cardiovascular system. Copper Mountain, CO, August 1997.

Consultant, FASEB Summer Research Conference, Perinatal regulation of the cardiovascular system. Copper Mountain, CO, June 2000; Tucson AZ, August 2004.

Co-organizer, International Society for the study of Hypertension in Pregnancy Workshop: Oxygen sensing and trophoblast invasion. Toronto, June 2002

Organizing Committee, Fourth International Conference on Relaxin and Related Peptides. September 2004.

External advisor for NIH PO1 HD38843, Ron Magness, PI (University of Wisconsin, Madison, WI)

Workshop Chair, Renal & Cardiovascular Function during Pregnancy, International Society for the Study of Hypertension in Pregnancy, Lisbon, July 2-5, 2006.

Leadership Development Program Course, University of Pittsburgh School of Medicine, March-August 2006.

Mouse and Rat Microsurgical Techniques Workshop, Department of Orthopedic Surgery, Wake Forest University School of Medicine, October 18-20, 2006.

Bas Medical Inc. San Mateo, CA. June 2006 (Consultant on use of relaxin in heart failure).

Councilor, Society of Gynecological Investigation, 2007-2010.

Relaxin and Heart Failure Advisory Meeting. Corthera Inc. San Francisco, CA. May 2008.

Workshop Co-Chair, Matrix Metalloproteinases, International Society for the Study of Hypertension in Pregnancy, Washington DC, September 2008.

Chairman of the SGI Communications Committee, 2008-2010.

Nitrates Differentiation Workshop. Novartis Inc. Paris & Basel, September 2011.

Secretary Treasurer of the SGI, 2010-2014.

Chairman of the SGI Finance Committee and Compensation Committee, 2010-2014.

Chairman of the SGI Research Seed Fund Awards Committee. 2013-14

Organizer of the No Name Society 52nd Annual Meeting. Ghost Ranch. Abiquiu, NM. October 2013.

Serelaxin Mechanism of Action Advisory Board Meeting. Novartis Inc. Paris France. November 2013.

Serelaxin Mechanism of Action. Novartis East Hanover, NJ. April 2014.

External Advisor for COBRE for Reproductive Health. Surendra Sharma MD, PhD. Women and Infants Hospital-Warren Alpert Medical School of Brown University. April 2017.

Organizer of SRI Mini-symposium: Endometrial antecedents of adverse pregnancy outcomes. San Diego, CA. March 2018.

Chairman of the 8th International Conference on Relaxin and Related Peptides. Cabo San Lucas, Mexico. May 2018.

FULL AND PROVISIONAL PATENTS:

- 2004 U.S. Patent Application Serial No. 09/780,752 for
"Use of RELAXIN to treat DISEASES RELATED TO VASOCONSTRICTION"
Primary Inventor: CONRAD, KIRK P.
- 2005 U.S. Patent Application No. 11/084,670 for *"Use of RELAXIN to increase ARTERIAL COMPLIANCE"*
Primary Inventor: CONRAD, KIRK P.
- 2008 U.S. Patent filed for *"Gene Expression Related to Preeclampsia"*
Primary Inventor: CONRAD, KIRK P. US 13/119,213 filed 16 March 2011. The application published under number –US-2011-0171650-A1 on 14 July 2011
UF#-12733-US filed 3/16/2011-Published 7/14/2011.

- 2008 U.S. Provisional Patent filed for "*PREDICTION AND PREVENTION OF PREECLAMPSIA*"
Co-Inventor: CONRAD, KIRK P.
UF#-13036-Other Institution is Leading-University of Pittsburgh-Of the Commonwealth System-
US Filed 7/29/2011- Published 11/17/2011.
- 2010 PCT/US2011/027859 filed for "*METHOD FOR TREATING EDEMA AND NEPHROGENIC
DIABETIS INSIPIDUS*"
Co-Inventor: CONRAD, KIRK P.
UF#-13358-OTHER INSTITUTION IS LEADING-UNIVERSITY OF MELBOURNE-
111. (WO2011112791) *MODULATING AQUAPORINS WITH RELAXIN*
-
- 2011 U.S. Provisional Patent 14/240,842 filed for "*Materials and Methods for Increasing the Number
and Activity of Bone Marrow Derived Endothelial Cells*".
Co-Inventor: CONRAD, KIRK P.
- 2016 U.S. Patent 9,381,231. "*Use of Relaxin to Restore Maternal Physiology in Pregnancies
Conceived by ART*".
Inventor: Conrad, Kirk P.
- 2018 U.S. Patent 9,907,833. "*Use of Relaxin to Prevent Placental Syndromes*"
Inventor: Conrad, Kirk P.